Copy of NH1 and NHS - Premium Table as at July 1, 2010

合集下载

赴美疫苗接种证明中英文

赴美疫苗接种证明中英文疫苗接种以及疫苗接种证明对于赴美国的人员来说非常重要。

以下是一份关于疫苗接种证明的参考内容，包括中文和英文。

疫苗接种证明参考内容：中文：尊敬的领事馆领事，我有意前往美国旅行/工作/学习，为了履行相关国际防疫规定，我特此提供我的疫苗接种证明。

我已完成以下疫苗接种：1. 疫苗类型：COVID-19疫苗接种日期：20xx年xx月xx日接种剂次：1/2（第一/第二剂）2. 疫苗类型：乙肝疫苗接种日期：20xx年xx月xx日接种剂次：1/3（第一/第三剂）请您知悉，在接种上述疫苗的过程中，我遵循了相关医务人员的指导和要求，并完成了所有所需的疫苗接种剂次。

我相信这将有助于保护我自己以及他人免受疾病的侵害。

附上本人的疫苗接种证明，以供核实。

再次感谢您的支持与关注。

此致（您的姓名）英文：To whom it may concern,I am writing to provide my vaccination certificate as I am planning to travel/work/study in the United States. In order to comply with international health regulations, I have received the following vaccinations:1. Vaccine Type: COVID-19 VaccineDate of Administration: xx/xx/20xxDose: 1/2 (First/Second Dose)2. Vaccine Type: Hepatitis B VaccineDate of Administration: xx/xx/20xxDose: 1/3 (First/Third Dose)Please be informed that during the administration of the above-mentioned vaccines, I followed the guidance and requirements of healthcare professionals and completed all the required doses. I believe that this will help protect myself and others from the diseases.Attached is my vaccination certificate for verification purposes. Thank you once again for your support and attention.Sincerely, (Your Name)。

BD Vacutainer

IMPORTANT MIXING GUIDELINES All BD Vacutainer® tubes require immediate mixing following collection. Insufficient mixing can result in inaccurate test results and the need to re-draw. Correct mixing technique is to invert each tube by the recommended number of times shown on the right hand side of the table.BD Diagnostics - Preanalytical Systems The Danby Building Edmund Halley Road Oxford Science Park Oxford OX4 4DQ Tel: 01865 781603Fax: 01865 781528BD, BD Logo, Vacutainer and Hemogard are trademarks of Becton, Dickinson and Company ©2014 BD.Mix8-10TimesBD Vacutainer®BD Diagnostics - Preanalytical SystemsTube Guide & Recommended Order of Draw** Clinical and Laboratory Standards Institute (Formerly NCCLS) Guidelines H3-A6, 6th EditionBlood samples must be taken in the following order:North Bristol NHS TrustGeneral WardsCap ColourAdditiveTestsSpecial Instructions1Blood CultureAerobic followed by Anaerobic - if insufficient blood for both culture bottles, use Aerobic bottle only.2Sodium CitrateClotting studies, INR, Heparin monitoring, Warfarin monitoring, D-Dimer.Tube MUST be filled to the full draw volume.3SST TMIIU&Es, LFT, Calcium, Lipids, Thyroid function test, CRP , Amylase, Magnesium, Vitamin B12, Folate, Ferritin, Serum electrophoresis, Antibiotic assays, Immunology, Serology, Lithium, etc.4EDTAFull blood count, plasma viscosity, immunosuppressants, Haemoglobin A1c, Parathyroid hormone, Sickle cell &thalassaemia, Malaria screens, ammonia.5EDTATransfusion samples (Group & save, cross match, antenatal).6Fluoride OxalateGlucose, Lactate, Ethanol.7Trace ElementZinc, Selenium, Aluminium, Copper, etc.For further copies of this guide and questions regarding specific tests,please contact the main Pathology Laboratory.Mix3-4TimesMix5-6TimesMix8-10TimesMix8-10TimesMix8-10TimesMix8-10Times。

IATA AHM目录

Airport Handling ManualEffective 1 January—31 December 201838NOTICEDISCLAIMER. The information contained in thispublication is subject to constant review in the lightof changing government requirements and regula-tions. No subscriber or other reader should act onthe basis of any such information without referringto applicable laws and regulations and/or withouttak ing appropriate professional advice. Althoughevery effort has been made to ensure accuracy, theInternational Air Transport Association shall not beheld responsible for any loss or damage caused byerrors, omissions, misprints or misinterpretation ofthe contents hereof. Furthermore, the InternationalAir Transport Association expressly disclaims anyand all liability to any person or entity, whether apurchaser of this publication or not, in respect ofanything done or omitted, and the consequencesof anything done or omitted, by any such person orentity in reliance on the contents of this publication.Opinions expressed in advertisements appearing inthis publication are the advertiser’s opinions and donot necessarily reflect those of IATA. The mentionof specific companies or products in advertisementdoes not imply that they are endorsed or recom-mended by IATA in preference to others of a simi-lar nature which are not mentioned or advertised.© International Air Transport Association. AllRights Reserved. No part of this publication maybe reproduced, recast, reformatted or trans-mitted in any form by any means, electronic ormechanical, including photocopying, record-ing or any information storage and retrieval sys-tem, without the prior written permission from:Senior Vice PresidentAirport, Passenger, Cargo and SecurityInternational Air Transport Association800 Place VictoriaP.O. Box 113Montreal, QuebecCANADA H4Z 1M1Airport Handling ManualMaterial No.: 9343-38ISBN 978-92-9229-505-9© 2017 International Air Transport Association. All rights reserved.TABLE OF CONTENTSPage Preface (xv)Introduction (xvii)General (1)AHM001Chapter0—Record of Revisions (1)AHM011Standard Classification and Numbering for Members Airport Handling Manuals (2)AHM012Office Function Designators for Airport Passenger and Baggage Handling (30)AHM020Guidelines for the Establishment of Airline Operators Committees (31)AHM021Guidelines for Establishing Aircraft Ground Times (34)AHM050Aircraft Emergency Procedures (35)AHM070E-Invoicing Standards (53)Chapter1—PASSENGER HANDLING (91)AHM100Chapter1—Record of Revisions (91)AHM110Involuntary Change of Carrier,Routing,Class or Type of Fare (92)AHM112Denied Boarding Compensation (98)AHM120Inadmissible Passengers and Deportees (99)AHM140Items Removed from a Passenger's Possession by Security Personnel (101)AHM141Hold Loading of Duty-Free Goods (102)AHM170Dangerous Goods in Passenger Baggage (103)AHM176Recommendations for the Handling of Passengers with Reduced Mobility(PRM) (105)AHM176A Acceptance and Carriage of Passengers with Reduced Mobility(PRM) (106)AHM180Carriage of Passengers with Communicable Diseases (114)AHM181General Guidelines for Passenger Agents in Case of SuspectedCommunicable Disease (115)Chapter2—BAGGAGE HANDLING (117)AHM200Chapter2—Record of Revisions (117)AHM210Local Baggage Committees (118)AHM211Airport Operating Rules (124)Airport Handling ManualPageChapter2—BAGGAGE HANDLING(continued)AHM212Interline Connecting Time Intervals—Passenger and Checked Baggage (126)AHM213Form of Interline Baggage Tags (128)AHM214Use of the10Digit Licence Plate (135)AHM215Found and Unclaimed Checked Baggage (136)AHM216On-Hand Baggage Summary Tag (138)AHM217Forwarding Mishandled Baggage (139)AHM218Dangerous Goods in Passengers'Baggage (141)AHM219Acceptance of Firearms and Other Weapons and Small Calibre Ammunition (142)AHM221Acceptance of Power Driven Wheelchairs or Other Battery Powered Mobility Aidsas Checked Baggage (143)AHM222Passenger/Baggage Reconciliation Procedures (144)AHM223Licence Plate Fallback Sortation Tags (151)AHM224Baggage Taken in Error (154)AHM225Baggage Irregularity Report (156)AHM226Tracing Unchecked Baggage and Handling Damage to Checked and UncheckedBaggage (159)AHM230Baggage Theft and Pilferage Prevention (161)AHM231Carriage of Carry-On Baggage (164)AHM232Handling of Security Removed Items (168)AHM240Baggage Codes for Identifying ULD Contents and/or Bulk-Loaded Baggage (169)Chapter3—CARGO/MAIL HANDLING (171)AHM300Chapter3—Record of Revisions (171)AHM310Preparation for Loading of Cargo (172)AHM311Securing of Load (174)AHM312Collection Sacks and Bags (177)AHM320Handling of Damaged Cargo (178)AHM321Handling of Pilfered Cargo (179)AHM322Handling Wet Cargo (180)AHM330Handling Perishable Cargo (182)AHM331Handling and Protection of Valuable Cargo (184)AHM332Handling and Stowage of Live Animals (188)AHM333Handling of Human Remains (190)Table of ContentsPageChapter3—CARGO/MAIL HANDLING(continued)AHM340Acceptance Standards for the Interchange of Transferred Unit Load Devices (191)AHM345Handling of Battery Operated Wheelchairs/Mobility AIDS as Checked Baggage (197)AHM350Mail Handling (199)AHM351Mail Documents (203)AHM353Handling of Found Mail (218)AHM354Handling of Damaged Mail (219)AHM355Mail Security (220)AHM356Mail Safety (221)AHM357Mail Irregularity Message (222)AHM360Company Mail (224)AHM380Aircraft Documents Stowage (225)AHM381Special Load—Notification to Captain(General) (226)AHM382Special Load—Notification to Captain(EDP Format and NOTOC Service) (231)AHM383Special Load—Notification to Captain(EDP NOTOC Summary) (243)AHM384NOTOC Message(NTM) (246)Chapter4—AIRCRAFT HANDLING AND LOADING (251)AHM400Chapter4—Record of Revisions (251)AHM411Provision and Carriage of Loading Accessories (252)AHM420Tagging of Unit Load Devices (253)AHM421Storage of Unit Load Devices (263)AHM422Control of Transferred Unit Load Devices (268)AHM423Unit Load Device Stock Check Message (273)AHM424Unit Load Device Control Message (275)AHM425Continued Airworthiness of Unit Load Devices (279)AHM426ULD Buildup and Breakdown (283)AHM427ULD Transportation (292)AHM430Operating of Aircraft Doors (295)AHM431Aircraft Ground Stability—Tipping (296)AHM440Potable Water Servicing (297)AHM441Aircraft Toilet Servicing (309)Airport Handling ManualPageChapter4—AIRCRAFT HANDLING AND LOADING(continued)AHM450Standardisation of Gravity Forces against which Load must be Restrained (310)AHM451Technical Malfunctions Limiting Load on Aircraft (311)AHM453Handling/Bulk Loading of Heavy Items (312)AHM454Handling and Loading of Big Overhang Items (313)AHM455Non CLS Restrained ULD (316)AHM460Guidelines for Turnround Plan (323)AHM462Safe Operating Practices in Aircraft Handling (324)AHM463Safety Considerations for Aircraft Movement Operations (337)AHM465Foreign Object Damage(FOD)Prevention Program (340)Chapter5—LOAD CONTROL (343)AHM500Chapter5—Record of Revisions (343)AHM501Terms and Definitions (345)AHM503Recommended Requirements for a New Departure Control System (351)AHM504Departure Control System Evaluation Checklist (356)AHM505Designation of Aircraft Holds,Compartments,Bays and Cabin (362)AHM510Handling/Load Information Codes to be Used on Traffic Documents and Messages (368)AHM513Aircraft Structural Loading Limitations (377)AHM514EDP Loading Instruction/Report (388)AHM515Manual Loading Instruction/Report (404)AHM516Manual Loadsheet (416)AHM517EDP Loadsheet (430)AHM518ACARS Transmitted Loadsheet (439)AHM519Balance Calculation Methods (446)AHM520Aircraft Equipped with a CG Targeting System (451)AHM530Weights for Passengers and Baggage (452)AHM531Procedure for Establishing Standard Weights for Passengers and Baggage (453)AHM533Passengers Occupying Crew Seats (459)AHM534Weight Control of Load (460)AHM536Equipment in Compartments Procedure (461)AHM537Ballast (466)Table of ContentsPageChapter5—LOAD CONTROL(continued)AHM540Aircraft Unit Load Device—Weight and Balance Control (467)AHM550Pilot in Command's Approval of the Loadsheet (468)AHM551Last Minute Changes on Loadsheet (469)AHM561Departure Control System,Carrier's Approval Procedures (471)AHM562Semi-Permanent Data Exchange Message(DEM) (473)AHM564Migration from AHM560to AHM565 (480)AHM565EDP Semi-Permanent Data Exchange for New Generation Departure Control Systems (500)AHM570Automated Information Exchange between Check-in and Load Control Systems (602)AHM571Passenger and Baggage Details for Weight and Balance Report(PWR) (608)AHM580Unit Load Device/Bulk Load Weight Statement (613)AHM581Unit Load Device/Bulk Load Weight Signal (615)AHM583Loadmessage (619)AHM587Container/Pallet Distribution Message (623)AHM588Statistical Load Summary (628)AHM590Load Control Procedures and Loading Supervision Responsibilities (631)AHM591Weight and Balance Load Control and Loading Supervision Training and Qualifications (635)Chapter6—MANAGEMENT AND SAFETY (641)AHM600Chapter6—Record of Revisions (641)AHM610Guidelines for a Safety Management System (642)AHM611Airside Personnel:Responsibilities,Training and Qualifications (657)AHM612Airside Performance Evaluation Program (664)AHM615Quality Management System (683)AHM616Human Factors Program (715)AHM619Guidelines for Producing Emergency Response Plan(s) (731)AHM620Guidelines for an Emergency Management System (733)AHM621Security Management (736)AHM633Guidelines for the Handling of Emergencies Requiring the Evacuation of an Aircraft During Ground Handling (743)AHM650Ramp Incident/Accident Reporting (745)AHM652Recommendations for Airside Safety Investigations (750)AHM660Carrier Guidelines for Calculating Aircraft Ground Accident Costs (759)Airport Handling ManualChapter7—AIRCRAFT MOVEMENT CONTROL (761)AHM700Chapter7—Record of Revisions (761)AHM710Standards for Message Formats (762)AHM711Standards for Message Corrections (764)AHM730Codes to be Used in Aircraft Movement and Diversion Messages (765)AHM731Enhanced Reporting on ATFM Delays by the Use of Sub Codes (771)AHM780Aircraft Movement Message (774)AHM781Aircraft Diversion Message (786)AHM782Fuel Monitoring Message (790)AHM783Request Information Message (795)AHM784Gate Message (797)AHM785Aircraft Initiated Movement Message(MVA) (802)AHM790Operational Aircraft Registration(OAR)Message (807)Chapter8—GROUND HANDLING AGREEMENTS (811)AHM800Chapter8—Record of Revisions (811)AHM801Introduction to and Comments on IATA Standard Ground Handling Agreement(SGHA) (812)AHM803Service Level Agreement Example (817)AHM810IATA Standard Ground Handling Agreement (828)AHM811Yellow Pages (871)AHM813Truck Handling (872)AHM815Standard Transportation Documents Service Main Agreement (873)AHM817Standard Training Agreement (887)AHM830Ground Handling Charge Note (891)AHM840Model Agreement for Electronic Data Interchange(EDI) (894)Chapter9—AIRPORT HANDLING GROUND SUPPORT EQUIPMENT SPECIFICATIONS (911)AHM900Chapter9—Record of Revisions (911)AHM901Functional Specifications (914)AHM904Aircraft Servicing Points and System Requirements (915)AIRBUS A300B2320-/B4/C4 (917)A300F4-600/-600C4 (920)A310–200/200C/300 (926)A318 (930)A319 (933)Table of ContentsPageChapter9—AIRPORT HANDLING GROUND SUPPORT EQUIPMENT SPECIFICATIONS(continued) AHM904Aircraft Doors,Servicing Points and System Requirements for the Use of Ground Support Equipment(continued)A320 (936)A321 (940)A330-200F (943)A330-300 (948)A340-200 (951)A340-300 (955)A340-500 (959)A340-600 (962)Airbus350900passenger (965)AIRBUS A380-800/-800F (996)ATR42100/200 (999)ATR72 (1000)AVRO RJ70 (1001)AVRO RJ85 (1002)AVRO RJ100 (1003)B727-200 (1004)B737–200/200C (1008)B737-300,400,-500 (1010)B737-400 (1013)B737-500 (1015)B737-600,-700,-700C (1017)B737-700 (1020)B737-800 (1022)B737-900 (1026)B747–100SF/200C/200F (1028)B747–400/400C (1030)B757–200 (1038)B757–300 (1040)Airport Handling ManualPageChapter9—AIRPORT HANDLING GROUND SUPPORT EQUIPMENT SPECIFICATIONS(continued) AHM904Aircraft Doors,Servicing Points and System Requirements for the Use of Ground Support Equipment(continued)B767—200/200ER (1041)B767—300/300ER (1044)B767—400ER (1048)B777–200/200LR (1051)B777–300/300ER (1055)Boeing787800passenger (1059)BAe ATP(J61) (1067)Bombardier CS100 (1068)Bombardier CS300 (1072)CL-65(CRJ100/200) (1076)DC8–40/50F SERIES (1077)DC8–61/61F (1079)DC8–62/62F (1081)DC8–63/63F (1083)DC9–15/21 (1085)DC9–32 (1086)DC9–41 (1087)DC9–51 (1088)DC10–10/10CF (1089)DC10–30/40,30/40CF (1091)EMBRAER EMB-135Regional Models (1092)EMBRAER EMB-145Regional Models (1094)Embraer170 (1096)Embraer175 (1098)Embraer190 (1100)Embraer195 (1102)FOKKER50(F27Mk050) (1104)FOKKER50(F27Mk0502) (1106)Chapter9—AIRPORT HANDLING GROUND SUPPORT EQUIPMENT SPECIFICATIONS(continued) AHM904Aircraft Doors,Servicing Points and System Requirements for the Use of Ground Support Equipment(continued)FOKKER70(F28Mk0070) (1108)FOKKER100(F28Mk0100) (1110)FOKKER100(F28Mk0100) (1112)IL-76T (1114)MD-11 (1116)MD–80SERIES (1118)SAAB2000 (1119)SAAB SF-340 (1120)TU-204 (1122)AHM905Reference Material for Civil Aircraft Ground Support Equipment (1125)AHM905A Cross Reference of IATA Documents with SAE,CEN,and ISO (1129)AHM909Summary of Unit Load Device Capacity and Dimensions (1131)AHM910Basic Requirements for Aircraft Ground Support Equipment (1132)AHM911Ground Support Equipment Requirements for Compatibility with Aircraft Unit Load Devices (1136)AHM912Standard Forklift Pockets Dimensions and Characteristics for Forkliftable General Support Equipment (1138)AHM913Basic Safety Requirements for Aircraft Ground Support Equipment (1140)AHM914Compatibility of Ground Support Equipment with Aircraft Types (1145)AHM915Standard Controls (1147)AHM916Basic Requirements for Towing Vehicle Interface(HITCH) (1161)AHM917Basic Minimum Preventive Maintenance Program/Schedule (1162)AHM920Functional Specification for Self-Propelled Telescopic Passenger Stairs (1164)AHM920A Functional Specification for Towed Passenger Stairs (1167)AHM921Functional Specification for Boarding/De-Boarding Vehicle for Passengers withReduced Mobility(PRM) (1169)AHM922Basic Requirements for Passenger Boarding Bridge Aircraft Interface (1174)AHM923Functional Specification for Elevating Passenger Transfer Vehicle (1180)AHM924Functional Specification for Heavy Item Lift Platform (1183)AHM925Functional Specification for a Self-Propelled Conveyor-Belt Loader (1184)AHM925A Functional Specification for a Self-Propelled Ground Based in-Plane LoadingSystem for Bulk Cargo (1187)Chapter9—AIRPORT HANDLING GROUND SUPPORT EQUIPMENT SPECIFICATIONS(continued) AHM925B Functional Specification for a Towed Conveyor-Belt Loader (1190)AHM926Functional Specification for Upper Deck Catering Vehicle (1193)AHM927Functional Specification for Main Deck Catering Vehicle (1197)AHM930Functional Specification for an Upper Deck Container/Pallet Loader (1201)AHM931Functional Specification for Lower Deck Container/Pallet Loader (1203)AHM932Functional Specification for a Main Deck Container/Pallet Loader (1206)AHM933Functional Specification of a Powered Extension Platform to Lower Deck/Container/ Pallet Loader (1209)AHM934Functional Specification for a Narrow Body Lower Deck Single Platform Loader (1211)AHM934A Functional Specification for a Single Platform Slave Loader Bed for Lower DeckLoading Operations (1213)AHM936Functional Specification for a Container Loader Transporter (1215)AHM938Functional Specification for a Large Capacity Freighter and Combi Aircraft TailStanchion (1218)AHM939Functional Specification for a Transfer Platform Lift (1220)AHM941Functional Specification for Equipment Used for Establishing the Weight of aULD/BULK Load (1222)AHM942Functional Specification for Storage Equipment Used for Unit Load Devices (1224)AHM950Functional Specification for an Airport Passenger Bus (1225)AHM951Functional Specification for a Crew Transportation Vehicle (1227)AHM953Functional Specifications for a Valuable Cargo Vehicle (1229)AHM954Functional Specification for an Aircraft Washing Machine (1230)AHM955Functional Specification for an Aircraft Nose Gear Towbar Tractor (1232)AHM956Functional Specification for Main Gear Towbarless Tractor (1235)AHM957Functional Specification for Nose Gear Towbarless Tractor (1237)AHM958Functional Specification for an Aircraft Towbar (1240)AHM960Functional Specification for Unit Load Device Transport Vehicle (1242)AHM961Functional Specification for a Roller System for Unit Load Device Transportation on Trucks (1245)AHM962Functional Specification for a Rollerised Platform for the Transportation of Twenty Foot Unit Load Devices that Interfaces with Trucks Equipped to Accept Freight ContainersComplying with ISO668:1988 (1247)AHM963Functional Specification for a Baggage/Cargo Cart (1249)AHM965Functional Specification for a Lower Deck Container Turntable Dolly (1250)AHM966Functional Specification for a Pallet Dolly (1252)Chapter9—AIRPORT HANDLING GROUND SUPPORT EQUIPMENT SPECIFICATIONS(continued) AHM967Functional Specification for a Twenty Foot Unit Load Device Dolly (1254)AHM968Functional Specification for Ramp Equipment Tractors (1256)AHM969Functional Specification for a Pallet/Container Transporter (1257)AHM970Functional Specification for a Self-Propelled Potable Water Vehicle with Rear orFront Servicing (1259)AHM971Functional Specification for a Self-Propelled Lavatory Service Vehicle with Rear orFront Servicing (1262)AHM972Functional Specifications for a Ground Power Unit for Aircraft Electrical System (1265)AHM973Functional Specification for a Towed Aircraft Ground Heater (1269)AHM974Functional Specification for Aircraft Air Conditioning(Cooling)Unit (1272)AHM975Functional Specifications for Self-Propelled Aircraft De-Icing/Anti-Icing Unit (1274)AHM976Functional Specifications for an Air Start Unit (1278)AHM977Functional Specification for a Towed De-Icing/Anti-Icing Unit (1280)AHM978Functional Specification for a Towed Lavatory Service Cart (1283)AHM979Functional Specification for a Towed Boarding/De-Boarding Device for Passengers with Reduced Mobility(PRM)for Commuter-Type Aircraft (1285)AHM980Functional Specification for a Self-Propelled Petrol/Diesel Refueling Vehicle forGround Support Equipment (1287)AHM981Functional Specification for a Towed Potable Water Service Cart (1289)AHM990Guidelines for Preventative Maintenance of Aircraft Towbars (1291)AHM994Criteria for Consideration of the Investment in Ground Support Equipment (1292)AHM995Basic Unit Load Device Handling System Requirements (1296)AHM997Functional Specification for Sub-Freezing Aircraft Air Conditioning Unit (1298)Chapter10—ENVIRONMENTAL SPECIFICATIONS FOR GROUND HANDLING OPERATIONS (1301)AHM1000Chapter10—Record of Revisions (1301)AHM1001Environmental Specifications for Ground Handling Operations (1302)AHM1002Environmental Impact on the Use of Ground Support Equipment (1303)AHM1003GSE Environmental Quality Audit (1305)AHM1004Guidelines for Calculating GSE Exhaust Emissions (1307)AHM1005Guidelines for an Environmental Management System (1308)Chapter11—GROUND OPERATIONS TRAINING PROGRAM (1311)AHM1100Chapter11—Record of Revisions (1311)AHM1110Ground Operations Training Program (1312)Appendix A—References (1347)Appendix B—Glossary (1379)Alphabetical List of AHM Titles (1387)IATA Strategic Partners..............................................................................................................................SP–1。

美国联合保健公司产品说明书：测试生成产品

UnitedHealthcare PharmacyClinical Pharmacy ProgramsProgram Number 2023 P 2018-16Program Prior Authorization/Medical Necessity – TestosteroneMedication Androderm, Androgel*, Fortesta*, Jatenzo*, Natesto*, Kyzatrex*,Testim, testosterone topical solution (generic Axiron)*, testosteronetransdermal gel (generic Testim)*, Tlando*, Vogelxo*, Xyosted*P&T Approval Date 2/2014, 4/2014, 5/2014, 7/2014, 10/2014, 10/2015, 5/2016, 6/2017,6/2018, 2/2019, 6/2019, 7/2020, 8/2021, 9/2022, 1/2023Effective Date 4/1/2023;Oxford only: 4/1/20231.Background:Testosterone products are approved by the Food and Drug Administration (FDA) for testosterone replacement therapy in males with primary hypogonadism (congenital or acquired) orhypogonadotropic hypogonadism (congenital or acquired). Primary hypogonadism originatesfrom a deficiency or disorder in the testicles. Secondary hypogonadism indicates a problem in the hypothalamus or the pituitary gland. Testosterone use has been strongly linked to improvements in muscle mass, bone density, and libido.The purpose of this program is to provide coverage for androgens and anabolic steroid therapy for the treatment of conditions for which they have shown to be effective and are within the scope of the plan’s pharmacy benefit. Coverage for the enhancement of athletic performance or bodybuilding will not be provided.a3.Additional Clinical Rules:•Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)and/or claim logic. Use of automated approval and re-approval processes varies by programand/or therapeutic class.•Supply limits may be in place.•* May be excluded from coverage•+ Coverage for patient population may be dependent upon benefit design4.References:1.AACE Hypogonadism Task Force. American Association of Clinical EndocrinologistsMedical Guidelines for Clinical Practice for the Evaluation and Treatment ofHypogonadism in Adult Male Patients – 2002 Update. Endocr Pract. 2002; 8(No. 6): 439-456.2.The World Professional Association for Transgender Health (WPATH), Standards of Carefor the Health of Transsexual, Transgender, and Gender Nonconforming People, 7thVersion.3.Cook, David M, et al. "American Association of Clinical Endocrinologists medicalguidelines for clinical practice for growth hormone use in growth hormone-deficient adultsand transition patients - 2009 update: executive summary of recommendations." Endocrinepractice 15.6 (2009):580-586.4.Gibney, James, et al. "Growth hormone and testosterone interact positively to enhanceprotein and energy metabolism in hypopituitary men." American journal of physiology:endocrinology and metabolism 289.2 (2005):E266-E2715.Bhasin, S, et al. "Testosterone replacement and resistance exercise in HIV-infected menwith weight loss and low testosterone levels." JAMA. 2000. 283.(6) 763-770.6.Isidori, Andrea M, et al. Effects of testosterone on sexual function in men: results of ameta-analysis. Clinical endocrinology. 2005 63(4):381-394.7.Kenny, A M, et al. Effects of transdermal testosterone on bone and muscle in older menwith low bioavailable testosterone levels. The journals of gerontology. 2001. 56(5) M266-M272.8.Tracz, Michal J, et al. Testosterone use in men and its effects on bone health. A systematicreview and meta-analysis of randomized placebo-controlled trials. The Journal of clinicalendocrinology and metabolism. 2006. 91(6):2011-2016.9.Bolona, Enrique R, et al. Testosterone use in men with sexual dysfunction: a systematicreview and meta-analysis of randomized placebo-controlled trials. Mayo Clinicproceedings.2007. 82(1):20-28.10.Androderm [package insert]. Madison, NJ: Allergan, Inc; May 2020.11.Androgel [package insert]. North Chicago, IL: AbbVie Inc; May 2020.12.Fortesta [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; January 2022.13.Testim [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; August 2021.14.Natesto [package insert]. Mississauga, ON: Acerus Pharmaceuticals Corporation;December 2021.15.Vogelxo [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; April2020.16.Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab 2017; 102:3869.17.The Endocrine Society. Testosterone therapy in Adult Men with Androgen DeficiencySyndromes. J Clin Endocrinol Metab, May 2018, 103(5):1–30.18.Mulhall JP, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline.American Urological Association Education and Research, Inc 2018.19.Xyosted [package insert]. Ewing, NJ: Antares Pharma, Inc; November 2019.20.Jatenzo [package insert]. Northbrook, IL: Clarus Therapeutics, Inc; March 2019.21.Tlando [package insert]. Ewing, NJ: Antares Pharma, Inc; March 2022.22.Kyzatrex [package insert]. Raleigh, NC: Marius Pharmaceuticals LLC; September 2022.Program Prior Authorization/Medical Necessity - TestosteroneChange ControlDate Change2/2014 Create Prior Authorization Criteria4/2014 Revised Reauthorization Criteria; formatting corrections, referencesupdated.5/2014 Revised the initial authorization criteria to include subsections for themale population and the female to male transsexual population, updatedto include language from the gender identity disorder/ gender dysphoriatreatment medical coverage determination guideline, referencesupdated7/2014 Added Natesto and Vogelxo to criteria. Changed coverage criteria fromspecific product names to topical testosterone products.10/2014 Modified criteria for total testosterone to consider reference range of thelaboratory. Added criteria for when Free Testosterone level may beutilized. Added criteria for conditions that do not require testosteronelevels. Extended initial authorization period for patients already ontherapy.12/2014 Testosterone free level units corrected.10/2015 Clarified initial authorization periods. Clarified that levels forreauthorization should be within the past 6 months for patients new totestosterone and within the past 12 months for continuing users.Updated references.5/2016 Removed age requirement from female to male transsexual coveragerequirements. Updated gender identity disorder to gender dysphoria.6/2017 Updated criteria for Gender Dysphoria. Updated reauthorizationcriteria to clarify that new to therapy refers to use of less than one yearand continuing therapy refers to use of one year or longer.6/2018 Updated required testosterone level to less than 300 ng/dL based on2018 American Urological Society treatment guidelines.2/2019 Program name change from Topical Androgens to Testosterone.Xyosted added to program.6/2019 Jatenzo added to program.7/2020 Updated initial authorization to 6 months for both new and existingusers. Added state mandate language. Updated references.8/2021 Annual review. Updated references. Removed Striant as it is no longeron the market.9/2022 Tlando added to program. Removed brand Axiron from program sinceit is no longer available. Updated to note generic Testim is typicallyexcluded. Updated references.1/2023 Kyzatrex added to program. Increased initial authorization to 12months and changed reauthorization to require a lab value within thepast 12 months.。

Draft Guidance for Industry and Food and Drug Administration Staff

Draft Guidance for Industry and 1 Food and Drug Administration2 Staff3 45 eCopy Program for Medical Device6 Submissions78 DRAFT GUIDANCE910 This guidance document is being distributed for comment purposes only.11 Document issued on: [use release date of FR Notice]1213 You should submit comments and suggestions regarding this draft document within 30 days of 14 publication in the Federal Register of the notice announcing the availability of the draft guidance. 15 Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug 16 Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic17 comments to . Identify all comments with the docket number listed in 18 the notice of availability that publishes in the Federal Register . 1920 For questions regarding this document, contact the Premarket Notification (510(k)) Section or 21 the Premarket Approval Section of CDRH at 301-796-5640 or CBER’s Office of 22 Communication, Outreach and Development at 1-800-835-4709 or 301-827-1800. 23 2425262728U.S. Department of Health and Human Services 29 Food and Drug Administration 30 Center for Devices and Radiological Health 31 Center for Biologics Evaluation and Research32Preface3334Additional Copies3536Additional copies are available from the Internet. You may also send an e-mail request to37dsmica@ to receive an electronic copy of the guidance or send a fax request to 301-38827-8149 to receive a hard copy. Please use the document number (1797) to identify the39guidance you are requesting.4041Additional copies of this guidance document are also available from the Center for Biologics42Evaluation and Research (CBER), Office of Communication, Training and Manufacturers43Assistance (HFM-40), 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448, or by44calling 1-800-835-4709 or 301-827-1800, or from the Internet at45/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/defau 46lt.htm.4748Table of Contents491.Introduction (1)502.What is an eCopy? (2)513.Are differences between the contents of an eCopy and paper submission acceptable? 2 524.For what submission types would an eCopy be required? (3)535.What submission types would FDA consider exempt from submission of an eCopy? .4 546.What submission types or applicants should be eligible for an eCopy waiver? (4)557.How many copies of a submission would be needed? (4)568.What are the processing steps for an eCopy? (5)57a. What are the standards for an eCopy? (5)58b. How do I know if my eCopy meets FDA’s standards for acceptance?? (6)59c. What if there is another processing party involved? (6)60d. How do you submit an eCopy to FDA? (6)61e. How does FDA process an eCopy? (7)629.What if your device is regulated by CBER? (7)63a. Will the new eCopy Program apply? (7)64b. Can you submit an electronic submission instead? (7)65c. How do you prepare and submit an electronic submission to CBER? (8)66Attachment 1 –Standards for eCopies (7)67A. Cover Letter that accompanies an eCopy (10)68B. Volume versus non-volume structure (11)69C. Folder naming convention for volume-based submissions that house PDF files (13)70D. Adobe Acrobat PDF file format (14)71E. Non-PDF file formats (15)72F. PDF file naming convention (16)73G. PDF file size limit (17)74H. Creating a PDF version from the source document (17)75I. Bookmarks and hypertext links within PDFs (20)76J. PDFs created from scanning paper documents (21)77K. Common mistakes in creating an eCopy (22)7879Guidance for Industry and Food and Drug 80Administration Staff8182eCopy Program for Medical Device83Submissions84851.Introduction86The purpose of this guidance is to explain the new electronic copy (eCopy) Program for medical 87device submissions. At this time, submission of an eCopy of a medical device submission is88voluntary. However, section 745A(b) of the Federal Food, Drug, and Cosmetic Act (FD&C89Act), added by section 1136 of the Food and Drug Administration Safety and Innovation Act90(FDASIA) (Pub. L. 112-144), requires the submission of eCopies after this guidance is finalized.91This draft guidance describes how the Food and Drug Administration (FDA) plans to implement 92the eCopy Program under section 745A(b) of the FD&C Act. The inclusion of an eCopy is93expected to improve the efficiency of the review process by allowing for the immediate94availability of an electronic version for review rather than relying solely on the paper version.9596This draft guidance provides, among other things, the standards for a valid eCopy under section 97745A(b)(2)(A) of the FD&C Act. In accordance with section 745A(b), following the issuance of98a final guidance on this topic, submission types identified in the final guidance must include an99eCopy in accordance with the standards provided by this guidance for the submission to be100processed and accepted for review by FDA. Submissions submitted without an eCopy and101eCopy submissions that do not meet the standards provided in this guidance will be placed on 102hold until a valid eCopy is submitted to FDA and verified to meet the standards, unless a waiver 103or exemption has been granted. While the submission is on hold, the review clock will not104begin.105106In Section 745A(b), Congress granted explicit statutory authorization to FDA to implement the 107statutory eCopy requirement by providing standards, criteria for waivers, and exemptions in108guidance. Accordingly, to the extent that this document provides such requirements under109section 745A(b) of the FD&C Act (i.e., standards, criteria for waivers, and exemptions),110indicated by the use of the words must or required,this document is not subject to the usual111restrictions in FDA’s good guidance practice (GGP) regulations, such as the requirement that 112guidances not establish legally enforceable responsibilities. See 21 CFR 10.115(d).113114However, this document also provides guidance on FDA’s interpretation of the statutory eCopy 115requirement and the Agency’s current thinking on the best means for implementing other aspects 116of the eCopy program. Therefore, to the extent that this document includes provisions that are 117not “standards,” “criteria for waivers,” or “exemptions” under section 745A(b)(2), this document 118does not create or confer any rights for or on any person and does not operate to bind FDA or the 119public, but will represent the Agency’s current thinking on this topic when finalized. The use of 120the word should in such parts of this guidance means that something is suggested or121recommended, but not required. You can use an alternative approach if the approach satisfies 122Draft – Not for Implementationthe requirements of the applicable statutes and regulations. If you want to discuss an alternative 123approach, contact the FDA staff responsible for implementing this guidance. If you cannot124identify the appropriate FDA staff, call the appropriate number listed on the title page of this125guidance.126127To comply with the GGP regulations and make sure that regulated entities and the public128understand that guidance documents are nonbinding, FDA guidances ordinarily contain standard 129language explaining that guidances should be viewed only as recommendations unless specific 130regulatory or statutory requirements are cited. FDA is not including this standard language in 131this draft guidance because it is not an accurate description of all of the effects of this guidance, 132when finalized. This guidance, when finalized, will contain both binding and nonbinding133provisions. Insofar as this guidance, when finalized, provides “standards,” “criteria for waivers,” 134and “exemptions” pursuant to section 745A(b) of the FD&C Act, it will have binding effect. For 135these reasons, FDA is not including the standard guidance language in this draft guidance.136137The eCopy Program is not intended to impact (reduce or increase) the type or amount of data the 138applicant1 includes in a submission to support clearance or approval. Please refer to other FDA 139device or program-specific guidance documents from CDRH140(/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/defau 141lt.htm) and CBER142/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guida 143nces/General/ucm214106.htm) for the appropriate contents for submissions.1441452.What is an eCopy?146An electronic copy (eCopy) is defined as an exact duplicate of the paper submission, created and 147submitted on a compact disc (CD), digital video disc (DVD), or in another electronic media148format that FDA has agreed to accept, accompanied by a copy of the signed cover letter and the 149complete original paper submission.21501513.Are differences between the contents of an eCopy and152paper submission acceptable?153While an eCopy is defined as an exact duplicate of the paper copy, there are limited cases in154which differences between the eCopy and the paper copy may be justified because a paper copy 155is not practical or appropriate for analysis purposes (e.g., raw data and statistical analysis156programs,3 data line listings to facilitate a bioresearch monitoring review) or is not feasible (e.g., 157videos, x-rays). The critical attribute of an eCopy is that it must include in electronic form all 1581 For the purposes of this guidance, applicant includes “submitter,” “sponsor,” or “holder.”2 An eCopy is not considered to be an electronic submission. For information on eSubmissions, refer to “FDAeSubmitter” (/ForIndustry/FDAeSubmitter/default.htm) and “Regulatory Submissions inElectronic Format for Biologic Products”(/BiologicsBloodVaccines/DevelopmentApprovalProcess/ucm163685.htm).3 For information on electronically submitted data, refer to “Clinical Data for Premarket Submissions”(/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissi ons/ucm136377.htm).Draft – Not for Implementationdata required for that submission type.4 In other words, the eCopy must include all of the159required information for FDA review, whereas the paper copy can include a page cross-160referencing the location of certain information in the eCopy.161162The cover letter must contain the eCopy statement described in Attachment 1 and describe any 163differences between the paper version and the eCopy. The paper version must also have a164placeholder (e.g., a piece of paper printed with the appropriate section title or a divider165appropriately cross-labeled to the table of contents) that cross-references the eCopy to indicate 166that there are additional data/information in the eCopy and where in the eCopy that information 167is located.168169FDA will consider the eCopy loaded into the appropriate Center’s official document repository 170to be the official record. Any undisclosed differences between the eCopy and the paper version 171may need to be rectified and could delay the review of the submission.1721734. For what submission types is an eCopy required?174Once FDA finalizes this guidance, section 745A(b) of the FD&C Act, as added by section 1136 175of FDASIA, will require an eCopy for the following submission types5:176•Premarket notification submissions (510(k)s), including third party 510(k)s;177•Evaluation of automatic class III designation petitions (de novos);178•Premarket approval applications (PMAs)6;179•Modular PMAs;180•Transitional PMAs;181•Product development protocols (PDPs);182•Investigational device exemptions (IDEs);183•Humanitarian device exemptions (HDEs), including Humanitarian Use Device184designation requests (HUDs);185•Certain investigational new drug applications (INDs)7;186•Certain biologics license applications (BLAs)8; and187•Pre-Submissions9.1884 For example, the content requirements for a 510(k) submission are found in 21 CFR 870.87 and 807.92; those fororiginal PMA submissions are found in 21 CFR 814.20.5 Although not subject to the eCopy legislation, FDA accepts and strongly encourages eCopies for Master AccessFiles (“MAF” submissions), 513(g) Requests for Classification (“C” submissions), and Clinical LaboratoryImprovement Act (CLIA) Categorization – Exempt Device submissions (“X” submissions). If you choose to submit an eCopy, it must meet the standards outlined in Attachment 1.6 This includes all PMA submission types, including, but not limited to, original PMAs, panel-track supplements,180-day supplements, manufacturing site change supplements, and post-approval study supplements.7 Applicable only to those devices regulated by CBER that are also biologics under section 351 of the Public HealthService (PHS) Act and that also require submission of an IND prior to submission of a BLA. Such devices aregenerally those intended for use in screening donated blood for transfusion transmissible diseases.8 Applicable only to those devices regulated by CBER that are also biologics under Section 351 of the PHS Act,including those that do not require submission of an IND prior to the submission of the BLA. Such devicesgenerally include those reagents used in determining donor/recipient compatibility in transfusion medicine inaddition to those for use in screening blood for transfusion transmissible diseases.9 Refer to the draft guidance entitled, “Medical Devices: The Pre-Submission Program and Meetings with FDAStaff” (/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm310375.htm).Draft – Not for Implementation189eCopies for all subsequent submissions to an original submission, including amendments,190supplements, and reports10 to the submission types identified above would also be required even 191if the original was submitted to FDA prior to implementation of the eCopy requirement.1921935.What submission types does FDA consider exempt from 194submission of an eCopy?195Due to the potential urgent nature of the following types of submissions, FDA considers these to 196be exempt from the requirement for an eCopy:197•Compassionate use IDE submissions;198•Emergency use IDE submissions11; and199•Emergency Use Authorizations (EUAs)12.200201However, we encourage you to submit eCopies of these submissions, when feasible, in order to 202facilitate the review process. In addition, this exemption would not preclude you from sending 203in pertinent electronic information, such as imaging data, as supporting information for these 204submission types when an eCopy is not submitted.2052066.What submission types or applicants are eligible for an207eCopy waiver?208FDA believes that, given the widespread availability of software to enable the creation of an209acceptable eCopy at little to no cost, all applicants should have the ability to provide an eCopy. 210Therefore, at this time, FDA does not anticipate the need for waivers, except as described in211Section 9.2122137.How many copies of a submission are needed?214The eCopy Program would not change the overall number of copies to submit to FDA. Upon 215finalization of this guidance document, an eCopy (with a signed cover letter) will serve as one of 216the required number of copies for the various submission types. (See Table 1 below.) FDA will 217accept additional eCopies (each with a signed cover letter) in lieu of additional paper copies as 218long as at least one paper copy is submitted along with the eCopy and the total number of219required copies remains the same.22022110 Reports include all reports submitted to an applicable submission type, including annual/periodic and post-approval reports. Section 745A(b) of the FD&C Act does not apply to Medical Device Reports submitted under 21 CFR Part 803 .11 Please refer to CDRH’s device advice page entitled “IDE Early/Expanded Access”(/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDevi ceExemptionIDE/ucm051345.htm#compassionateuse) and FDA’s “Guidance on IDE Policies and Procedures”(/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080202.htm) for additional details on compassionate and emergency use IDE submissions.12 Refer to the guidance entitled, “Emergency Use Authorization of Medical Products”(/RegulatoryInformation/Guidances/ucm125127.htm) for more information on EUAs.Draft – Not for ImplementationFor submission types for which only two copies are required to be submitted, one must be an 222eCopy and the other must be a paper copy. For submission types requiring more than two223copies, this policy would allow additional flexibility in how the application is submitted. For 224example, for an original PMA, you would submit: (1) one eCopy and five paper copies; (2) five 225eCopies and one paper copy; or (3) any other combination that results in six total copies as long 226as there is at least one eCopy and one paper copy.227228Table 1, provides the total number of copies to be submitted to FDA. As explained above, you 229must submit at least one eCopy and one paper submission. The format for the remaining copies 230(i.e., eCopy or paper) is your choice.231232Table 1 – Number of Copies for Submission233Submission Type Total Number ofCopies510(k)s 213Third Party 510(k)s 213Original PMAs and Panel-Track Supplements 614Other PMA supplement types 315PMA reports 2Modular PMAs 3HDEs Same as PMAs,16except for HUDdesignationrequests, whichrequire two.17PDPs Same as PMAsIDEs 318INDs 319BLAs 3Pre-Submissions 32348.What are the processing steps for an eCopy?235Below are the processing steps for the submission and acceptance of an eCopy.236237a.What are the standards for an eCopy?238With regard to the standards for an eCopy submitted to FDA, please refer to Attachment 2391. Because an eCopy cannot be accepted by our eCopy loading system if it does not meet 240the standards, you should carefully review this information.24124213 See 21 CFR 807.90(a)(3)(c).14 See 21 CFR 814.20(b)(2).15 See 21 CFR 814.39(c).16 See 21 CFR 814.104(b)(4).17 See 21 CFR 814.102(d).18 See 21 CFR 812.20(a)(3).19 See 21 CFR 312.23(d).b.How do I know before submission whether my eCopy meets FDA’s243standards for acceptance?244To confirm that your eCopy will meet FDA’s standards, we strongly encourage you to 245use the new free eSubmitter-eCopies tool available on FDA’s website at246/ForIndustry/FDAeSubmitter/ucm317334.htm. One of the benefits of 247utilizing the eSubmitter-eCopies tool is that it creates an eCopy in real-time that is248consistent with the standards. Use of the eSubmitter-eCopies tool is intended to prevent 249delays in review of your submission due to the need to resolve technical issues.250Although it is highly encouraged, you will not be required to utilize the eSubmitter-251eCopies tool and may choose to skip the eSubmitter step.252253Should you have any technical questions when generating your eCopy, please contact 254cdrhesub@ prior to submission of the eCopy to FDA.255256c.What if there is another processing party involved?257In the case that another party (e.g., law firm, consultant) submits a submission on behalf 258of an applicant, the eCopy must still meet the standards for an eCopy in order to be259successfully processed whether accomplished by you (the applicant) or the submitting 260party. While the applicant may or may not include their own cover letter as part of the 261eCopy, our standards require that the submitting party include a signed cover letter with 262an eCopy statement, as described in Attachment 1.263264In the case of Third Party 510(k)s, two separate CDs comprise the eCopy. The first CD 265includes the applicant’s submission and should be clearly marked as such. The contents 266of the CD must include a cover letter with an eCopy statement, as described in267Attachment 1, that the applicant has provided. The second CD includes the Accredited 268Person’s review records and should be clearly marked as such. The Accredited Person is 269responsible for ensuring that the CDs meet the standards in Attachment 1 for an eCopy. 270In addition, the Accredited Person is responsible for providing a signed cover letter that 271includes an eCopy statement, as described in Attachment 1, that speaks to both: (1) the 272Accredited Person’s portion of the eCopy and (2) the presence of the eCopy statement 273provided by the applicant. It is not sufficient for the Accredited Person to address only 274one of these two eCopy statement issues in their cover letter.275276d.How do you submit an eCopy to FDA?277An eCopy is submitted simultaneously with the paper submission(s). First, attach the 278signed cover letter with the eCopy statement to your eCopy. Then attach this eCopy279package to the paper submission(s) and send them to CDRH’s or CBER’s Document280Control Center20 (DCC). An eCopy that is sent to the DCC without a cover letter and 281accompanying paper submission(s) will be placed on hold.282283If more than one eCopy is to be submitted, then you must attach a signed cover letter as 284described above to each additional eCopy.28528620 Refer to 21 CFR 807.90 for the DCC addresses for CDRH and CBER.e.How does FDA process an eCopy?287If an eCopy passes the validation check, the cover letter and eCopy contents will be288loaded into the appropriate Center’s official submission repository.289290If an eCopy fails the validation check (i.e., is rejected), we will notify you in writing291(e.g., by email or fax) of the reason(s). The notification will describe the logistics for 292submitting a replacement eCopy, including how to properly mark it as a replacement293eCopy, the address to which to send it, and the submission number to write on it. It is 294important that you follow these directions to avoid delays in processing the replacement 295eCopy. The submission will be placed on hold until a valid replacement eCopy is296submitted to FDA and verified to meet the standards.2972989.What if your device is regulated by CBER?299a.Will the new eCopy Requirement apply?300Yes, unless your submission is an entirely electronic submission exempted under this 301guidance, as described below. Upon implementation of the statutory requirement, all 302medical device submission types listed in Section 4 must be accompanied by an eCopy 303regardless of the Center in FDA in which the submission will be reviewed unless the304requirement is waived or exempted. Accordingly, submissions for devices subject to 305review under the FD&C Act and submitted by filing paper copies with CBER’s DCC 306must be accompanied by an eCopy, except where exempted as described below.307308While many submissions made to CBER are still in paper format and require submission 309of multiple copies, CBER is also currently able to receive and manage submissions that 310are entirely electronic.311312Submissions for devices that are subject to licensure under the Public Health Service313(PHS) Act, including biologics license applications and supplements, investigational new 314drug applications, and EUAs and pre-submissions for these devices, may be submitted as 315entirely electronic submissions as detailed in sections 9b and 9c below. FDA will316exempt such entirely electronic submissions from the eCopy requirement.317318FDA additionally waives the eCopy requirement to submit paper copies of any entirely 319electronic submission made to CBER. Accordingly, entirely electronic submissions that 320comply with CBER guidance identified in Section 9.c. below do not need to be321accompanied by paper copies.322323b.Can you submit an electronic submission instead?324Yes, and there are several advantages for both industry and for CBER staff when you 325choose to make submissions electronically.326327The main advantage to you is in the financial savings that will likely result. The costs 328associated with printing, binding, labeling, and shipping multiple paper copies can be 329significant, especially for submissions that contain a great deal of supporting330Draft – Not for Implementationdocumentation. Likewise, we anticipate that FDA will recognize financial savings in that 331FDA avoids the costs associated with tracking, routing, and storing large amounts of332paper when you choose to submit electronically.333334Another advantage with the use of the electronic submission process is that all parties 335involved in the submission and review are referencing the same document – the336electronic one. There is no question about whether the paper copy is an exact copy of the 337eCopy. Electronic submissions may also reduce the need for reviewers to request re-338submission of previously submitted information due to an inability to read or interpret the 339information on the paper copy, as sometimes occurs when documents are photocopied. 340341c.How do you prepare and submit an electronic submission to CBER?342CBER has several resources available to applicants who choose to submit electronic343submissions as outlined in the document “Regulatory Submissions in Electronic Format 344for Biologic Products.”345(/BiologicsBloodVaccines/DevelopmentApprovalProcess/ucm163685 346.htm). Thus, specific details are available in the cited references and will not be repeated 347in this guidance.348349For devices that are regulated under the PHS Act and require the submission of a BLA, 350consult the guidance document entitled “Providing Regulatory Submissions to the Center 351for Biologics Evaluation and Research (CBER) in Electronic Format - Biologics352Marketing Applications”353(/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulator 354yInformation/Guidances/General/UCM192413.pdf) for details on preparing your355electronic submission. Note that certain sections of this guidance, for example, those on 356pharmacology and toxicology, are generally not pertinent to licensed devices.357358For guidance on preparing electronic submissions for other device submissions (e.g.,359510(k)s, PMAs) sent to CBER, please see “Guidance for Industry: Providing Regulatory 360Submissions in Electronic Format - General Considerations”361(/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances 362/UCM072390.pdf) and “CBER SOPP 8110: Submission of Paper Regulatory363Applications to CBER”364(/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformati 365on/ProceduresSOPPs/ucm079467.htm), which includes information about providing366electronic copies to CBER.367368We are currently developing additional, updated guidance for other electronic369submissions sent to CBER and have issued a revised, updated draft guidance document 370for comment entitled, “Draft Guidance for Industry: Providing Regulatory Submissions 371in Electronic Format-General Considerations”372(/RegulatoryInformation/Guidances/ucm124737.htm). When373finalized, this document will provide an additional resource for applicants preparing374electronic submissions.375376。

九英(试卷)

2021学年第二学期适应性练习九年级英语试卷（满分140分，时间90分钟）2022.6考生注意：本卷有7大题，共84小题。

试题均采用连续编号，所有答案务必按照规定在答题纸上完成，做在试卷上不给分。

Part 1Listening (第一部分听力)I.Listening comprehension (听力理解)（共25分）A.Listen and choose the right picture (根据你听到的内容，选出相应的图片)（5分）ABCD E F1.______2.______3.______4.______5.______B.Listen to the dialogue and choose the best answer to the question you hear (根据你听到的对话和问题，选出最恰当的答案)（5分）()6.A)His sister.B)His father.C)His brother.D)His mother.()7.A)Basketball.B)Volleyball.C)Football.D)Table tennis.()8.A)At 7:00.B)At 7:30.C)At 8:00.D)At 8:30.()9.A)In a car.B)In a hotel.C)In a shop.D)In a restaurant.()10.A)Tony is too tired to go out.B)Kate doesn’t like going out.C)Kate expects to go out for dinner.D)Tony promised Kate a gift.C.Listen to the passage and tell whether the following statements are true or false (判断下列句子是否符合你听到的短文内容，符合的用“T ”表示，不符合的用“F ”表示)（5分）奥孚培优优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优()11.John is lucky enough to be a host of the school radio club.()12.At first the club was started to broadcast the news at break .()13.Now more kinds of music are provided by the club.()14.The radio club is very useful to the students and parents.()15.The article is mainly about the introduction of a school radio club.D.Listen to the dialogue and complete the following sentences (听对话，完成下列内容，每空格限填一词)(10分)16.Movies have a history of just ______________years.17.When movies were first created,they were not ______________.18.______________people can take part in movie making now.19.Adventure movies take people on ______________,to escape life or explore it.20.Jenny likes the movies acted by Charlie Chaplin —a ______________.Part 2Grammar and Vocabulary（第二部分语法和词汇）II.Choose the best answer (选择最恰当的答案)（共15分）()21.Sam didn’t tell ______truth until I met him in the street.A)a B)an C)/D)the()22.Mandy is quite pleased ______her son’s good behavior at school.A)for B)with C)ofD)by ()23.The boy was old enough to take the underground by ______.A)he B)him C)hisD)himself()24.Eric is a person who likes chatting with ______.A)another B)otherC)others D)the others()25.People who work in an office aren’t as ______as those who can work from anywhere.A)happy B)happier C)happiest D)the happiest ()26.Mum usually wakes me up ______after she gets ready for breakfast.A)lovely B)friendly C)gentlyD)lonely()27.–______is Guangzhou Metro Line 18?–It is 176km per hour.A)How fastB)How long C)How soonD)How many()28.Students ______be careful when they have swimming classes.A)can B)must C)mayD)need()29.While the young mum ______,her baby suddenly cried in the bedroom.A)cooked B)was cookedC)was cooking D)would cook()30.The headmaster said all the students ______already ______learning online for twomonths.A)were ...keeping B)were ...kept C)have ...kept D)had ...kept ()31.Drivers should consider ______more electric cars instead of fuel cars.奥孚培优优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优奥孚培优A)use B)to use C)using D)used()32.The special effects make the film ______wonderful.A)seem B)seems C)seemed D)to seem()33.Which would you like to read now,the novel ______the newspaper?A)soB)orC)but D)for()34.Jessica won’t finish writing her report ______she stays up late tonight.A)since B)when C)because D)unless ()35.______convenient it is to ride a mobike in rush hours!A)How B)What C)What aD)What anplete the following passage with the words in the box.Each can only be used once(将下列单词填入空格。

科研机构免税进口科学研究用品具体流程

英文回答：The process for a research institution to import scientific research supplies duty-free entails several crucial steps. Initially, the institution must acquire the requisite certification as a qualified research organization eligible for duty-free import. This may necessitate the submission of documentation to the pertinent government authorities, demonstrating the institution's legitimacy as a research entity. Upon obtaining the certification, the institution can then proceed to select the specific scientific research supplies for importation. This may require collaboration with suppliers and manufacturers to ensure that the products meet the necessary criteria for duty-free import, and may also involve securing any mandatory permits or licenses for the specific items being imported.研究机构免税进口科研用品的过程需要若干关键步骤。

缅甸GMP药品注册原文

UNION OF MYANMARMinistry of HealthDepartment of HealthFood and Drug Administration35, Min Kyaung Street, Dagon Township, Yangon, Myanmar.(Phone. 95-1-245332)Initial application for Registration1. An application for registration of drug must be submitted to the Department ofHealth, Food and Drug Administration in the original prescribed form (Form 1 Registration). Form (1) is available at one hundred kyats each at office of the Food and Drug Administration.2. Separate registration has to be applied for pharmaceutical preparations of differentstrength or different dosage form. For parenteral preparations these requirement is applicable also to different pack size.3. Form 1 must be filled out in type print. Enclosures submitted together withapplication form shall be marked with proper reference. A form which is filled incompletely or improperly will not be accepted.4. Form (1) must also be accompanied with two sets of documents on completeinformation of drugs. (See Annex-I for type of documentation required). Documents have to be submitted in file in an order as listed in "Documents Required for Registration of Drugs." A list of documents submitted should be shown on the first sheet of the file.5. An application with incomplete documentation will not be accepted.6. (a) An application must be submitted in person by an authorized representativeof owner of drug. (Product licence holder at country of origin) Any application made by mail or facsimile or means other than in person, will not be accepted. An authorized representative has to be a resident in Myanmar.(b) Should an authorization for representation be granted to the local company,the representative has to be a company employee authorized to serve as a contact person.7. Registration assessment fees must have been remitted to Myanmar Foreign TradeBank (MFTB) in favour of Drug Advisory Committee Account N. (91892) when submission of the application form is made.8. (a) If it is an application for registration of drugs manufactured outside Myanmar.The Food and Drug Administration will issue "Approval for importation of of DrugSamples" (Annex II) after receiving application. The drug samples as specified in the approval shall then be imported into the country. Te holder of the approval shall comply not only with the conditions stipulated in the approval but also with the regulations of Commerce and Customs Department.(b) As per Ministry of Health Notification 3/93 dated 5-8-93 paragraph 5, priorapproval shall be obtained from Food and Drug Administration for importation of sample drug. For the importation of sample drug without prior approval of the FDA, the FDA will not issue approval certificate.9. (a) The following kind of drug samples are normally required.- Drug samples the quantity of which is sufficient for clinical trial on sixtypatients. For certain rare diseases fewer numbers of samples may beacceptable.- Samples for laboratory analysis- Samples for retention.(b) For the total numbers of sample drugs to be submitted, please refer toFDA circular 1/97 (a) "Required quantities of sample drugs for registration"(Annex III)(c ) All drug samples must be accompanied with their respective analyticalreport (the certificate of analysis). The name and designation of an officialwho signs the report must be stated. The photocopy of report is notacceptable.10. The evaluation process for registration will be started only when all therequirements for registration application have been met; viz: (a) remittance of Registration Assessment Fees, (b) complete set of documents, (c) sufficient quantity of drug samples.11. (a) When the drug is approved for registration, the applicant will be notified toremit 200.00 United States dollar as Registration Fees. The notificationwill be made only on the notice board of FDA.(b) Failure to remit Registration Fees within 90 days from the date ofintimation will constitute forgoing of an application by an applicant. Ifso happens, neither the Registration Assessment Fees remitted norregistration documents and drug samples will be returned.12. Failure to make a follow-up of an application by an applicant for more thansix months from the date of remittance of assessment fees, will be taken as forgoing of an application.13. The Registration Certificate (Form II) will be issued only when theacknowledgement of receipt, of payments is submitted, issued by MFTB submitted.14. The submitted dossiers are not reclaimable in case of rejection of application.Updating Changes to Registered Drugs1. Updating changes to registered drugs shall be made only with the approval ofFood and Drug Administration.2. For this purpose, the holder of Registration Certificate shall apply for Variation ofRegistration; to FDA, stating(a) reason for change.(b) relevant data or findings from studies on which is based the justification ofchange.(c ) significant effect of changes to the specifications of drug.3. The following shall be submitted together with the application:(a) The attestation by country's drug regulatory authority to approval of suchchanges. If the regulatory authority's attestation cannot be provided, explainthe reason for it.(b) A photo copy of Registration Certificate of drug.4. (a) When it is decided to approve of changes, US$ 100 feeswill be levied on an applicant. The Drug Advisory Committee may waive thisrequirement if it believes that change is of benefit to public as regtards quality,safety and efficacy of drugs.(b) An original Registration Certificate must then be submitted to make approvedamendments on the certificate.Renewal of Registration1. Application for renewal of registration shall be submitted 90 days before the validityof the registration terminates. Failure to adhere to the 90 days requirement may result in disruption of continued validity of registration.2. Application shall be submitted in the same anner as prescribed for application forregistration of drug.3. The drug samples for clinical trial are normally not required. However if thesituation warrants the repeat-clinical trial, the samples will be asked. The samples for laboratory analysis and for retention are still required. Please refer to FDA circular 1/97 b "Required quantities of sample drug for analysis and retention."(Annex IV)4. The documentary requirement is the same as that of an initial application (SeeType of documents required for registration Annex I). Information provided, however, has to be updated. New findings which had not been submitted in an initial application have to be submitted too.5. Registration Assessment fees must have been remitted to the Drug AdvisoryCommittee Account No. 91892 at the time of application of renewal of registration.When the renewal of registration is approved of, two hundred United States dollar must be remitted as Registration Fees.6. Upon approval of renewing, new Registration Number will be designated, whichshall make the old Registration Number void.7. Failure to apply for renewal of registration shall result in invalidation of registrationwith effect from the date of expiry of the certificate.Fees levied1. Registration Assessment Fees 100 US$ + Fees (in Kyats) for2. Registration Fees 200 US$ laboratory analysis3. Variation of Registration 100 US$Note : (1) & (2) are levied either for fresh registration or renewal or registration.Registration of Active Pharmaceutical Raw Materials1. Documentary requirementsA. Administrative Documents1. A certificate of product issued by the regulatory authority of its owncountry that the product is authorized to be sold in country of origin.2. (a) Properly endorsed photocopy of valid manufacturing licence.(b) GMP certificate of manufacturing plant.3. A letter of authorization for legal representation of manufacturer (ower ofproduct in Myanmar.4. A business registration certificate of local representatives.B. Pharmaceutical Documents1. Generic name2. Chemical name3. Empirical & Structural Chemical formula4. Pharmacopoeia to which the product conforms.5. Pharmaceutical specifications (including physical characteristics, solubility,identification, loss on drying, sulphated, ash, heavy metal, purity, assay,etc.)6. Method of analysis7. Manufacturing process8. Quality Assurance System (including control of starting material, in-process control, finished raw material control, packaging control, etc.).9. Certificate of analysis.10. Stability test report of at least three different batches.11. Recommended Shelf-life.12. Recommended Storage conditions.13. Packaging specifications.2. Fees Amounts(a) Assessment fees US$ 100 + Fees in Kyats for laboratory analysis(b) Registration fees US$ 200(c ) Variation fees US$ 1003. Application shall be made in the same manner as prescribed for registrationapplication of finished product.4. A sample (20 gm) has to be submitted together with the dossier. The sample mustbe packed & labeled properly. An approval of FDA for importation of sample raw material is also required.(Annex-I) Type of documents required for registration of drugs1. Administrative Documents1. A letter of authorization of legal representative of owner of drug issued to anapplicant.Note : (i) Owner of drug shall inform FDA of any changes of person(s)representing him in Myanmar. Any consequences arising out offailure to inform so, shall be the responsibility of owner of drug.(ii) For continued representation, the applicant shall submit fromtime to time, as required by the validity of authorization, arenewed letter of authorization from owner of drug.2. A company profile (For company whose products have not been registeredbefore in Myanmar).3. The certificate of Pharmaceutical Products in a format adopted by WHO forCertification Scheme on the quality of Pharmaceutical Products moving inInternational Commerce. [(a) An original certificate must be submitted. Stickalways to the updated format. (b) If valid period is not stated on the certificate,the certificate shall not be older than one year at time of submission.) (SeeAnnex-V)4. GMP certificate and properly endorsed photocopy of manufacturing licence.5. Proforma statement (See Annex-VI).6. Completely filled "Summary Drug Information Sheet" (See Annex-VII)II. Pharmaceutical Documents1. Name of Drug (brand name, generic name).2. Formula and composition with necessary reference to its justification (whereapplicable).3. The pharmacopoeia (For preparations being listed in either B.P, USP or Eu.Phr., they must conform to BP, USP or Eu. Phr. standards. In exception, forpreparations not being listed in above pharmacopoeias, the standards of thepharmacopoeia other than BP, USP or Eu. Phr. may be accepted.) to whichactive substances and excipients conform. If it is a New Chemical Entity, therelevant references must be provided.4. Data on physical and chemical properties, structural and empirical formula ofactive substances and excipients (where applicable).5. Analytical methods for active substances and excipients. The pharmacopoeiato which they conform.6. Quality Control of Raw Material.(a) Standard control procedure (control on supplier, accept/reject system,quarantine/release system, sampling procedure, test parameters andtesting methods reporting and record keeping system etc.)(b) Raw material specifications.(c) Specimen Q.C. Report on raw material.(d) Attestation to above particulars by a responsible person not lower thanQ.C. Manager. Signature, name and designation should be printed onthe attestation.7. Manufacturing process.8. Standard procedure for In-process Quality Control.(a) Accept/reject system.(b) Sampling procedure.(c) Test parameters and testing methods.(d) Reporting and record keeping system.(e) Specimen in-process Q.C. Report.(f) Attestation to above particulars by a responsible person not lower thanQ.C. Manager. Signature, name and designation should be printed onthe attestation.9. Finished Product.(a) Specifications, inclusing detailed description of physical characteristics.(b) Detailed composition of capsule shell, tablet coating.(c) Disintegration and dissolution profile.(d) Analytical methods and its parameters tested; the pharmacopoeia towhich it conforms.(e) A sample copy of certificate of analysis.(f) Stability test report (testing method, test parameters, testing condition including temperatures, humidity, type of packing)(i) Testing condition which is similar to climatic condition of tropical countries is preferred.(ii) Test done on drugs in its orginal packing(s) for which the application is made, is required.(iii) Test reports on at least three different batches have to be submitted.(g) Recommended shelf life and storage condition citing relevant data for making such claim.10. PackagingThe following are required to be submitted for all types of packaging that are applied for registration. Lack of any of them in the submitted dossier would result in non-consideration for approval of respective packagings.(a) type of package, its shape, size, color.(b) nature of packaging material.(c) pack size.(d) specimen package.(e) specimen label.(f) Specimen package insert.(g) quality control procedure on label and packaging, and its specimen Q.C. report.III. Pharmacological & Clinical Documents (For common established me-too drugs, the pharmacological and clinical data may be left out, unless there are new findings on them.)1. Data on basic pharmacological and microbiological studies.(a) Toxicity data(b) Teratogenicity data(c) Mutagenicity data(d) Data on efficacy and general pharmacology(e) Data on pharmacokinetics2. Data on Clinical Studies(a) Phase 1, Phase II, Phase III and IV where applicable(b) Clinical Pharmacokinetics(c) Bio-availability(d) Drug interactionsAnnex IIIDEPARTMENT OF HEALTHFOOD & DRUG AMINISTRATIONCircular No. 1/97 aRequired quantities of sample drugs for initial registrationNo. Drug Category Required QuantitiesTablets/ Syrup/Sus Injection TopicalCapsules/ pension/ (Ampoules/ (Tubes/Unit Dose Elixir (Up Vials) Bot.) Bot.)to 120ml)1. Anti-bacterial 2500 100 750 350 1002. Anti-fungal 2000 750 1003. Anti-viral 20004. Anti-malarial 2000 6505. Anti-tuberculous 3000 7506. Anti-amoebic 2000 100 600 3507. Anthelmintic(a) Single dose 150 doses 100(b) Multiple does 500 doses 1008. Anti-inflammatory 2000 100 400 100Drugs (Non-steroidol)9. Anti-deapessant 3000 60010. Anti-psychotic 3000 60011. Anti-convulsant 2000 100 35012. Anti-parkinsonism 400013. Anxiolytic 2000 40014. Anti-diabetic 2000 25015. Anti-thyroid 500016. Anti-emetic 2000 100 45017. Anti-diarrhoeal 200018. Antispasmodic 2000 45019. Antacid 2000 10020. Anti-ulcer 2000 100 45021. Anti-asthmatic 2000 100 60022. Antitussive 2000 10023. Antihistamine 2000 100 350 10024. Mucolytic 2000 10025. Anti-anginal 2000 35026. Anti-hypertensive 2000 45027. Anti-arrhythmic 2000 45028. Beta a dentergic blickers 2000 35029. Calcium Antagonnist 2000 35030. Diuretic 2000 20031. Anti-hyperlipidaemic 400032. Anti-haemorrhoidal 200033.* Anti-neoplastic34. Anti-migraine 200035.* Anaesthetics36. Amino Acids 2000 100 (LVP)350 (SVP)37. Antianaemic 2000 45038. Cold Remedy 2000 10039. Contraceptive 200 cycles40. corticosteroids 3000 350 10041. Intravenous 100 (LVP)Replacement Fluids 350 (SVP)42. Plasma Expander 10043. I/V Glucose (10%, 35025%, 50%)44. Multivitamin 2000 100 35045. Nootropics 3000 45046. (a) Oral RehydrationSalt tablets 700(b) Oral Rahydration 200Salt Powder Sachets(one litrepack)400 Sachets(less thanone litrepack)47. Uricosurics 200048.* Vaccines49. Dematologicals 10050. Eye/Ear Drops 100 LVP = Large Volume Parenteral, SVP = Small Volume Parenteral.(500 ml & above) (less than 500 ml)Note: (1) For those with (*) markings and for controlled medicine please check with FDA for exact number(2) All the submitted sample drugs must have a minimum of two years' shelf –life(3) In case of large sized packs (e.g. 500's, 1000's litre pack or jar) the required amounts are 7 bottles or boxes for 500 sized packs 1 litre packs or 1 kg jars & 5 bottles or boxes for 1000 sized packs and packs which are more than 1 litre or 1 kg sizes.(4) If more than one type of packagings or pack sizes are applied simultaneously for registration any one of small sized packs may conform to the prescribed amounts. The remainings have to be submitted in a minimum of four unit-pack each if it is a small sized pack and two unit-pack each if it is a large sized pack.Annex IVDEPARTMENT OF HEALTHFOOD & DRUG AMINISTRATIONCircular No. 1/97 aRequired quantities of sample drugs for initial registrationNo. Drug Category Required QuantitiesTablets/ Syrup/Sus Injection TopicalCapsules/ pension/ (Ampoules/ (Tubes/Unit Dose Elixir (Up Vials) Bot.) Bot.)to 120ml)1. Anti-bacterial 500 20 50 20 152. Anti-fungal 500 20 50 153. Anti-viral 500 20 50 154. Anti-malarial 500 505. Anti-tuberculous 500 506. Anti-amoebic 500 20 50 207. Anthelmintic(a) Single dose 50 20(b) Multiple does 50 208. Anti-inflammatory 500 20 50 15Drugs (Non-steroidol)9. Anti-deapessant 500 20 5010. Anti-psychotic 500 20 5011. Anti-convulsant 500 20 5012. Anti-parkinsonism 500 20 5013. Anxiolytic 500 20 5014. Anti-diabetic 500 5015. Anti-thyroid 50016. Anti-emetic 500 20 5017. Anti-diarrhoeal 500 2018. Antispasmodic 500 20 5019. Antacid 500 2020. Anti-ulcer 500 20 5021. Anti-asthmatic 500 20 5022. Antitussive 500 2023. Antihistamine 500 20 5024. Mucolytic 500 2025. Anti-anginal 500 5026. Anti-hypertensive 500 5027. Anti-arrhythmic 500 5028. Beta a dentergic blickers 500 5029. Calcium Antagonnist 500 5030. Diuretic 500 5031. Anti-hyperlipidaemic 50032. Anti-haemorrhoidal 50033.* Anti-neoplastic34. Anti-migraine 500 20 5035.* Anaesthetics36. Amino Acids 500 100 (LVP)50 (SVP)37. Antianaemic 500 20 5038. Cold Remedy 500 2039. Contraceptive 50 cycles40. Corticosteroids 500 5041. Intravenous 100 (LVP)Replacement Fluids 50 (SVP)42. Multivitamin 500 20 5043. Nootropics 500 20 5044. (a) Oral RehydrationSalt tablets 100(b) Oral Rahydration 30 SachetsSalt Powder (1L pack)50 Sachets(<1Lpack)45. Uricosurics 50046.* Vaccines47. Dematologicals 1548. Eye/Ear Drops 15 LVP = Large Volume Parenteral, SVP = Small Volume Parenteral.(500 ml & above) (less than 500 ml)Note: (1) For those with (*) markings and for controlled medicine please check with FDA for exact number(2) All the submitted sample drugs must have a minimum of two years' shelf –life(3) In case of large sized packs (e.g. 500's, 1000's litre pack or jar) the required amounts are 7 bottles or boxes for 500 sized packs 1 litre packs or 1 kg jars & 2 bottles or boxes for 1000 sized packs and packs which are more than 1 litre or 1 kg sizes.(4) If more than one type of packagings or pack sizes are applied simultaneously for registration any one of small sized packs may conform to the prescribed amounts. The remainings have to be submitted in a minimum of four unit-pack each if it is a small sized pack and two unit-pack each if it is a large sized pack.Annex V。

海运术语缩略语

海运术语缩略语&海运术语缩写?(2010-04-15 13:27:09)转载A/W?全水路?All?WaterANER?亚洲北美东行贸易术语运费协定?Asia?NorthAmerica?EastboundRate B/L?海运提单?Bill?of?LadingB/R?买价?Buying?RateB海运AF?燃油附加费?Bunker?AdjustmentFactorC&F?成本加海运费?COST?AND?FREIGHTC.C?运费到付?CollectC.S.C?货柜服务费?Container?Service?ChargeC.Y.?货柜场?Container?YardC/(CNEE)?收货人?ConsigneeC/O?产地证?Certificate?of?OriginCAF?货币汇率附加费?Currency?Adjustment?FactorCFS?散货仓库?Container?Freight?StationCFS/CFS?散装交货（起点/终点）CHB?报关行?Customs?House?BrokerCIF?成本，保险加海运费?COST，INSURANCE，FRIGHTCIP?运费、保险费付至目的地?Carriage?and?Insurance?Paid?ToCOMM?商品?CommodityCPT?运费付至目的地?Carriage&nb中国海运网sp;Paid?ToCTNR?柜子?Conta海运贸易术语inerCY/CY?整柜交货（起点/终点）D/A?承兑交单?Document?Against?AcceptanceD/O?到港通知?Delivery?OrderD/P?付款交单?Document?Against?PaymentDAF?边境交货?Delivered?At?FrontierDDC?目的港码头费?Destination?Delivery?ChargeDDP?完税后交货?Delivered?Duty?PaidDDU?未完税交货?Delivered?Duty?UnpaidDEQ?目的港码头交货?Delivered?Ex?QuayDES?目的港船上交货?Delivered?Ex?ShipDoc#?文件号码?Document?NumberEPS?设备位置附加费?Equipment?Position?SurchargesEx?工厂交货?Work/ExFactoryF/F?货运代理?Freight?ForwarderFAF?燃料附加费?F海运术语ess啥意思uel?AdjustmentFactorFAK?各种货品?Freight?All?KindFAS?装运港船边交货?Free?Alongside?ShipFCA?货交承运人?Free&股票术语nbsp;CarrierFCL?整柜?Full?Container?LoadFeeder?Vessel/Lighter?驳船航次FEU?40‘柜型?Forty-Foot?Equivalent?Unit?40’FMC?联邦海事委员会?Federal?Maritime?CommissionFOB?船上交货?Free?On?BoardGRI?全面涨价?General?RateIncreaseH/C?代理费?Handling?ChargeHBL?子提单?House?B/LI/S?内销售?Inside?SalesIA?各别调价?Independent?ActionL/C?信用证?Letter?of?Credit海运门Land?Bridge?陆桥LCL?拼柜?Less?Than?Container?LoadM/T?尺码吨（即货物收费以尺码计费）?Measurement?Ton MB/L?主提单?Master?Bill?Of?LoadingMLB?小陆桥，自一港到另一港口?Minni?Land?BridgeMother?Vessel?主线船MTD?多式联运单据?Multimodal?Transport?DocumentN/F?通知人?NotifyNVOCC?无船承运人?Non?Vessel?OperatingCommon?Carrier O/F?海运费?Ocean?FreightOBL?海运提单?Ocean?(or?original?)B/LOCP?货主自行安排运到内陆点?Overland?Continental?Point OP?操作?OperationORC?本地收货费用（广东省收取）?Origen?Recevie?Charges P.P?预付?PrepaidPCS?港口拥挤附加费?Port?Congestion?Surcharge宁波海运POD?目地港?Port?Of?DestinationPOL?装运港?Port?Of?LoadingPSS?旺季附加费?Peak?Season?SuchargesS/(Shpr)?发货人?ShipperS/C?售货合同?Sales?ContractS/O?装货指示书?Shipping?OrderS/R?卖价?Selling?RateS/S?Spread?Sheet?Spread?SheetSC?服务合同?Service?ContractSSL?船公司?Steam?Ship?LineT.O.C?码头操作费?Terminal?Operations?OptionT.R.C?码头收柜费?Terminal?Receiving?ChargeT/S?转船，转运?Trans-ShipT/T?航程?Transit?TimeTEU?20‘柜型?Twenty-Foot?Equivalent?Unit?20’THC?码头操作费（香港收取)?Terminal?Handling?Charges TTL?总共?TotalTVC/?TVR?定期定量合同?Time?Volume?Contract/?Rate VOCC?船公司?Vessel?Operating?Common?CarrierW/M?即以重量吨或者尺码吨中从高收费?Weight?or?Measurem国际海运术语ent?tonW/T?重量吨(即货物收费以重量计费)?Weight?TonYAS?码头附加费?Yard?Surcharges?史上最全航运术语和缩写2010-10-05 00:00分享史上最全航运术语和缩写?2010-03-18 14:42?|?(分类:锭)????? 缩写英文名称中文名称?一切险??value?实际现金价值?a.d.(a/) after date ...日期以后?A.F. ADVANCED FREIGHT 预付运费?空运运单?实际毛重,实际总重量?A.H. AFTER HATCH 后舱?A.N. ARRIVAL NOTICE 到达通知?A.O. account of ...的帐上?A.V. AD VALOREM ACCORDING TO?VALUE?运价标记,根据商品的价值(计算运费),从价费率A/C for account of 费用由...负担?A/or and/or 和/或?A/P account paid 已付帐款?A/R ALL RISKS 一切险?a/s after sight 见票后...?A/S alongside 靠码头,并靠他船?aa ALWAYS AFLOAT 保持漂浮,永远漂浮?AC account current 往来帐户，活期存款帐户，流通帐?ACC ALAMEDA CORRIDOR CHARGE 绿色通道费?acc. acceptance;accepted 已接受?acc.cop. according to the custom of the port 按照...港口惯例?ACCT ACCOUNT 帐目,帐户?ACPT ACCEPTANCE 接受?ad val.(a/v) ad valorem (according to?value) 从价费率(按离岸价格)?ADC ADVANCE CHARGES?ADCOM/M ADDRESS COMMISSION 订舱佣金,租船佣金?ADFT AFT DRAFT 艉吃水?ADP automated data processing 自动数据处理?ADR European Agreement concerning the international carriage of dangerous goods by road?ADV. ADVISE OR ADVANCE 通知或提前?AETR European Agreement concerning the work of crews of vehicles engaged in international roadAFC AMS Filing Charges 美国自动报关费?AFRA average freight rate assessment 运费费率平均运价?Agcy agency 代理公司,代理行?AGRD AGREED 同意?AGRT AGREEMENT 协议?Agt. agent 代理人?AGW ALL GOING WELL (取决于)一切顺利?AM ANTE MERIDIEM 上午?AMT AMOUNT 金额,数额?AMT Air Mail Transfer 航空邮寄?approx. approximately 大约?arr. arrival 到达,抵达?arrd. arrived 到达,抵达?ASAP AS SOON AS POSSIBLE 尽快,尽速?ASF AS FOLLOWS 如下?ass. associate 准会员,公司?ATA actual time arrival 实际到达时间?ATD actual time of departure 实际出发时间?ATFI Automated Tariff Filing and Information System 自动费率报备系统?ATP Agreement for the International Carriage of Perish able Foodstuffs?ATTN ATTENTION 由...收阅?Atty attorney 律师(美),代理人?auth. authorized 授权的,认可的?aux. auxiliary 辅助的,辅助设备?AWB Air Waybill 空运单?燃油附加费?燃油附加费系数?B.C. bulk cargo 散装货?包括始末两天?B.RGDS BEST REGARDS 致敬,致意?B.T. BERTH TERMS 班轮条款?B.W. bonded warehouse 保税仓库?B/D bank(ers) draft 银行汇票?B/G bonded goods 保税货物?B/L BILL OF LADING 提单?BA BALE CAPACITY 包装容积?BAF Bunker Adjustment Factor 燃油附加费?BAL BALANCE 平衡?BDL BUNDLE 捆?bdth breadth 宽度,型宽?Bdy boundary 边境,界线?BEAM BREADTH OF THE VESSEL (船舶)型宽?BENDS BOTH ENDS 装卸港?BIMCO BALTIC INTERNATIONAL MARITIME CONFERENCE 波罗的海国际航运公会?BIZ BUSINESS 业务?Bk. bank 银行?BKC/BC Bunker Charge 燃油附加费?Bkge brokerage 佣金,经纪费?BL BALE 包(装)?BLADING BILL OF LADING 提单?BLFT BALE FEET 包装尺码(容积)?BLK BULK 散装?BLKR BULKER 散装船?BP Base Port 基本港?brl. barrel 桶,分英制美制两种?BS/L BILLS OF LADING 提单(复)?bxs. boxes 盒,箱?C&F COST AND FREIGHT 货价加运费?c.&d. collection and delivery 运费收讫,货物交毕? 货币贬值附加费系数?货币贬值附加费?C.B. container base 集装箱底?交货前付现?C.F. CUBIC FEET 立方英尺?C.H. carriers haulage 承运业?货物装卸费?交货前付现款?成本,保险费,运费,加汇费价格?成本,保险费,运费,加利息价格?成本,保险费,运费,佣金,加汇费价格?成本,保险费,运费,佣金,加利息价格?成本,保险费,运费,利息,加汇费价格?成本,保险费,运费,利息,加佣金价格?伦敦条款到岸价格?到岸价加战争险?货到付款?铁路)装运集装箱的平板车?装船付船?C.P. Customs of Port 港口惯例?C.T. conference terms 公会条款?C/D customs declaration 报关单?C/N consignment note 发货通知书?C/O (IN) CARE OF 由...转交?C/O certificate of origin 原产地证明?C/P CHARTER PARTY 租船合同?C/P blading charter party bill of lading 租船提单? C/T Container Terminal 集装箱码头? CABLEADD CABLE ADDRESS 电报挂号?CAC currency adjustment charge 货币贬值附加费?CAConf Cargo Agency Conference(IATA) 货运代理公会?CAF Currency Adjustment Factor 币值调整附加费?CAF Currency Adjustment Factor 币值调整费?CASS Cargo Accounts Settlement System(IATA) 货运费用结算系统?cbm cubic meter 立方米?CBP Customs and Border Protection 美国海关边防总署?CC CARBON COPY 抄送?cc charges collect 收取运费?CCL customs clearance 清关?CCS consolidated cargo(container) service 集中托运业务?CEM European Conference on goods train timetables 欧洲货运列车时刻表会议?CFR Cost and freight (Incoterms) 成本加运费价?CFS CONTAINER FREIGHT STATION 集装箱货运站?CFS CFS Charge 集装箱场站费用?Ch.fwd charges forward 运费到付?CIC CHINA INSURANCE CLAUSE 中国保险条款?CIF COST,INSURANCE AND FRIEHGT 到岸价格(货价,保险费,加运费价)?CIF & C COST,INSURANCE,FREIGHT AND COMMISSION 到岸价格加佣金?CIM International Convention concerning the carriage of Goods by Railway?CIP Carriage and insurance paid to (Incoterms) 运费和保险费付至...(指定目的地)?CIV International Convention on the Carriage of Passenger and Luggage by Railway?CKD completely knocked down (unassembled) 完全分解的?CL.B/L CLEAN BILL OF LADING 清洁提单?cm centimetre(s) 厘米?cm3 cubic centimetre(s) 立方厘米?CMR Convention on the Contract for the International Carriage of Goods by Road?cnee consignee 收货人?cnmt/consgt. consignment 发运?cnor consignor 发货人?CO. COMPANY 公司?COA CONTRACT OF AFFREIGHTMENT 包运合同?COD Change of Destination 更改目的地（改港）?COD Charge of Diversion 转港费?COMBITERMS Delivery terms for intl groupage traffic 国际成组运输交货条款(货运代理人之间COMM. COMMISSION 佣金?CONBILL CONFERENCE BILL OF LADING 公会提单?CONGENBILL CONFERENCE GENERAL CARGO BILL OF LADING 公会杂货提单?CO-OP CO-OPERATION 合作?COP customs of port 港口惯例?CORP. CORPORATION 公司?COSCO CHINA OCEAN SHIPPING COMPANY 中国远洋运输总公司?COTIF Convention concerning Intl Carriage by Rail (CIM-CIV) 国际铁路运输公约?CP carriage paid 运费已付?CPLTC Conference Port Liner Term Charges 港口班轮装卸条款公会?CPT Carriage paid to (Incoterms) 运费付至(...指定目的地)?CQD CUSTOMARY QUICK DESPATCH 按港口惯常速度快速装卸?CSC Container service charge 集装箱运输费用?CSC Intl Convention of the Safe Transport of Containers 国际集装箱安全公约? CSConf Cargo Service Conference(IATA) 货运业公会?CST Container Service Tariff 集装箱运输费率?CT combined transport 联合运输?CTD combined transport document 联合运输单证?CTO combined transport operator 多式联运经营人?CTPC Cargo Traffic Procedures Committee(IATA)?cu.ft. cubic foot(feet) 立方英尺?cu.in. cubic inch(es) 立方英寸?CUB CUBIC 立方?CUC Chassis Usage Charge 拖车运费?CUC Chassis Usage 托盘使用费?CUFT CUBIC FEET 立方英尺?CUM CUBIC METER 立方米?CVGK customs?value?per gross kilogram (毛重)每公斤海关价值?CVGP customs?value?per gross pound (毛重)每磅海关价值?CWE cleared without examination 未经查验过关的?CWO CASH WITH ORDER 订货时预付款?cwt hundredweight 担,(英制)等于112磅,(美制)等于100磅?CY CONTAINER YAND 集装箱堆场?cy currency 货币?CYC CY HANDLING CHARGE 日本港口操作附加费?D DIESEL OIL 柴油?船边交货?D.F DEAD FREIGHT 空舱费?确报,船舶确切到港时间?D/A DOCUMENT AGAINST ACCEPTANCE 承兑交单?D/O DELIVERY ORDER 提货单?D/O Delivery Order 交货单（小提单）?D/P DOCUMENT AGAINST PAYMENT 付款交单?D/R Dock Receipt 场站收据?D300 DIESEL OIL 300 TONS 柴油300吨?DAF Delivery at frontier(Incoterms) 边境交货(...指定地)?Dbk drawback 退(关)税?DCAS Distribution Cost Analysis System 分拨费用分析系统?DCF Documentation Fee 单证费?DDC DEST. DELIVERY CHARGE 目的港卸货费?DDP Delivered duty paid(Incoterms) 完税后交货?DDU Delivered duty unpaid(Incoterms) 未完税交货?DEM DEMURRAGE 滞期费?DEP/DEPT DEPARTURE (船舶)离港?DEQ Delivered ex quay(duty paid)(Incoterms) 目的港码头交货(关税已付)?DES Delivered ex ship(Incoterms) 目的地船上交货(...指定目的港)?DESP DESPATCH MONEY 速遣费?DESPONENT OWNER SECOND OWNER OF THE SAME VESSEL 二船东?DFT DRAFT 吃水?DHC Dest. Terminal Handling Charge 目的港港口附加费?DHD DEMURRAGE AND HALF DESPATCH 滞期费,速遣费为滞期费的一半?DHDWTS DESPATCH HALF DEMURRAGE AND FOR WORKING TIME SAVED 速遣费按滞并按节省的工作时间计算?dia diameter 直径?DIB Destination Inland (Box) 目的港内陆附加费?dir. direct 直接?dm3 cubic decimetre(s) 立方分米?DOCIMEL Electronic Cim Document 电子单证?DWC DEADWEIGHT CAPACITY 受载量?DWCC dead weight cargo capacity 载重量?DWCT DEADWEIGHT CARGO TONNAGE 载重吨,受载量?DWT DEADWEIGHT TONNAGE 载重吨?DWTC DEADWEIGHT TONNAGE OF CARGO 货物载重吨?E.& O.E. ERRORS AND OMMISIONS EXCEPTED 有错当查(错误和遗漏不在此限)?E.G. EXAMPLE GRATIA=FOR EXAMPLE 例如?e.g. for example 例如?E/M EXPORT MANIFEST 出口载货清单,出口舱单?EBAF Emergent Bunker Adjustment Factor 紧急燃油附加费?EBS Emergency Bunker Surcharge 紧急燃油附加费?ECU European currency unit 欧洲货币单位?EDI electronic data interchange 电子数据交换?EDIFACT Electronic Data Interchange for Administration, Commerce and Transport?EDP electronic data processing 电子数据处理?EER Emergent Equip. Rest. Surcharge 紧急空箱调运费?EIR equipment interchange receipt(containers) 设备交接单(集装箱)?EIU EVEN IF USED 即使使用(也不算)?EMS Emergency Surcharge(near the war field) 紧急战争附加费?ENCL ENCLOSURE OR ENCLOSED 附件或所附的?ERS Equipment Re-positioning Surcharge 集装箱回空费?ERS EQUIP. REST. SURCH 空箱调运费?ETA ESTIMATED TIME OF ARRIVAL (船舶)预计抵港时间?ETAD EXPECTED TIME OF ARRIVAL AND DEPARTURE (船舶)预计到达和离开时间?ETB EXPECTED TIME OF BERTHING (船舶)预计靠泊时间?ETC EXPECTED TIME OF COMMENCEMENT 预计开始时间?ETCD ESTIMATED TIME OF COMMENCING DISCHARGING (船舶)预计开始卸货时间?ETD ESTIMATED TIME OF DEPARTURE (船舶)预计离港时间?ETL ESTIMATED TIME OF LOADING (船舶)预计开装时间?ETS ESTIMATED TIME OF SAILING (船舶)预计开航时间?excl. excluding 不包括,除...外?EXP EXPORT 出口?EXPS EXPENSES (费用)支出?EXW Ex works(Incoterms) 工厂交货(...指定地)?F FUEL OIL 燃油?一切海损不赔险?尽快(装卸)?货运代理人佣金?中等质量货物?F.and D. freight and demurrage 运费和滞期费?共同海损不赔险?船方不负担装货费和理舱费?驳船上交货??港内交货?船方)不负担装货,捆扎,加固,隔垫(料)等费用?船方不负担装卸费和理舱费?船方不负担装入货车费?方便国旗?损坏不赔?第一解冻日(保)?单独海损不赔?F/M EXPORT FREIGHT MANIFEST 出口载货运费清单,运费舱单?F300 FUEL OIL 300 TONS 燃油300吨?FAK freight all kinds (不分品种)同一费率?FALPRO Special Programme on Trade Facilitation(UNCTAD) 简化贸易手续特别计划?FAS Free alongside ship(Incoterms) 船边交货(...指定装运港)?FBL FIATA Multimodal Transport Bill of Lading(FIATA Document) FIATA 多式联运提单? FCA Free carrier(Incoterms) 货交承运人?FCL FULL CONTAINER LOAD (集装箱)整箱货?FCR Forwarders Certificate of Receipt (FIATA Document) 货运代理人收讫货物证明?FCSR & CC free of capture,seizure,riots and civil commotions 掳获,捕捉,暴动和内乱不赔险? FCT Forwarders Certificate of Transport(FIATA) 货运代理人运送证明?FDFT FORE DRAFT 艏吃水?FEU FOURTY EQUIVALENT UNIT 40标准集装箱?FFI FIATA Forwarding Instructions(FIATA form) 国际货运代理协会联合会代运说明?FHEX Friday and holidays excepted 节假日除外?FI FREE IN (船方)不负担装货费用?FILO FREE IN AND LINER OUT (船方)不负担装货费用,但负担卸货费用?FIO FREE IN AND OUT (船方)不负担装,卸费用?FIOST FREE IN AND OUT,STOWED AND TRIMMED (船方)不管装,不管卸,不管积载和平仓? firavv first available 最有效的?FIS freight,insurance and shipping charges 运费，保险和装船费用?FLT forklift truck 叉车?FLT FULL LINER TERMS 全班轮条款?FM FROM 从...,来自...?FMC Federal Maritime Commission 美国联邦海事委员会?FOB FREE ON BOARD 离岸价格(船上交货)?FPA FREE FROM PARTICULAR AVERAGE 平安险?FPAD freight payable at destination 目的地付运费?FR flat rack(container)?FRG FOR YOUR GUIDANCE 供你参考,供你掌握情况?FRT FREIGHT 运费?Frt.fwd. freight forward 到付运费?frt.ton freight ton 运费吨?FRZ Frozen 冰冻?FT FOOT OR FEET 英尺?ft.ppd. freight prepaid 运费预付?FWC full loaded weight & capacity(container) 满载重量和容积?FWD FORWARD 前部?FWDFT FRESH WATER DRAFT 淡水吃水?fwdr. forwarder 货运代理人?FWR FIATA Warehouse Receipt(FIATA Document) FIATA仓储收据?G.A. general average 共同海损(保)?共同海损协议(合同)?共同海损分摊额(保)?政府海运提单?G.C. general cargo 杂货?杂货费率?GA GENERAL AVERAGE 共同海损?GDP gross domestic product 国内生产总值?GENCON UNIFORM GENERAL CHARTER 统一杂货(程)租船标准合同,金康程租合同? GFA general freight agent 货运总代理?GMT GREENWICH MEAN TIME 格林威治标准时间?GNP gross national product 国民生产总值?GR GRAIN CAPACITY OR GROSS (船舶)散装容积或毛(重)?GRD GEARED 带吊杆的?GRI GEN RATE INCREASE 运费普遍增长?GRT GROSS REGISTER TONNAGE 总登记吨?GSA General Sales Agent 销售总代理?GSP GENERALIZED SYSTEM OF PREFERENCE 普惠制?GW GROSS WEIGHT 毛重?h.p. horse power 马力?H.Q. headquarters 总部?h/lift heavy lift 重件货?HA HATCH 舱口?HA DIM HATCH DIMENSION 舱口尺寸?HATUTC HALF TIME USED TO COUNT (AS LAYTIME) 实际所使用时间的一半应计算(为作HAWB House Air Waybill 货运代理运单,分运单?HBL House Bill of Lading 无船承运人提单?HD HEAVY DIESEL 重柴油?hdlg handling 处理,手续?HERMES Handling European Raiway Message Exchange-System 欧洲铁路运输信息交换系统? hgt height 高度?HO HOLD 货仓?HRS HOURS 小时?HTD Heated 加热?HTS Harmonized Tariff Schedule 国际货物编码?按照?I.E. ID EST=THAT IS 即是...,那就是...?借据,欠条?包括单独海损(保)?IAC Inter-modal Administrative Charge(U.S. Inland Surcharge) 内陆运输附加费?IAC Intermodel Administrative Charge 多式联运附加费?ICB International Carrier Bond 国际承运人保证金?ICC INSTITUTE CARGO CLAUSES,LONDON 伦敦协会货物条款(保险)?IFA Interim Fuel Adjustment 临时燃油附加费?IIC Indian Inland Charge 印度内陆费（包括：内陆费加费IHC、目的港DHC）?IMDG International Maritime Dangerous Goods Code 国际海运危险品编码?IMO IMCO additional 危险品附加费?IMP. IMPORT 进口?in. inch(s) 英寸?INC. INCLUDING 包括?incl. including 包括?INCOTERMS Standard condition for sale and delivery of goods 国际贸易术语解释通则? INMARSAT International Convention on the International Maritime Satellite Organization?INST INSTANT 本月的?INT INTENTION 意下,企图?INTRM intermediate point 中转点?inv. invoice 发票?IOP IRRESPECTIVE OF PERCENTAGE 不管百分比?IPF Inspection Fees 集装箱检查费?IU IF USED 如果使用?K.ATT KIND ATTENTION 请转,请交,请...收阅?KG KILOGRAM 公斤?KM KILOMETER 公里?时速?km2 square kilometre 平方公里?kn knot(s) 结?kW kilowatt 千瓦?kWh kilowatt-hour 度,千瓦时?l.& d. loss and damage 损失与残损?l.& u. loading and unloading 装卸?全长?L.T. LOCAL TIME 当地时间?L/A Lloyds agent 劳埃德保险公司代理人,劳埃德船级社代理人?L/C LETTER OF CREDIT 信用证?L/G LETTER OF GUARANTEE 保证书,保证信?L/L LOADING LIST 装货清单?L/T LONG TON 长吨?L/T liner terms 班轮条款?LABL Less Advance Booking Allowance 提前定舱优惠价?LADEN DRAFT THE DRAFT WHEN VESSEL IS LADEN (船舶)满载吃水? LASH lighter aboard ship 子母船?Lat.,lat. latitude 纬度?lb(s) pound(s) 磅?LBP LENGTH BETWEEN PERPENDICULARS (船舶)垂线间高?LCL Less Than Container Load 拼箱货?LCL LESS THAN CONTAINER LOAD (集装箱)拼箱货?LD LIGHT DIESEL 轻柴油?LDG leading 导航的,主要的?LDT LIGHT DEADWEIGHT 轻载重吨?leg. legal 法律上的,合法的?LEL lower explosive limit 最低爆炸极限?LFL lower flammable limit 最低燃烧极限?lgt. long ton;long tons 长吨?LH LOWER HOLD 底舱?LHC Loading port Terminal Handling Charge 装港港口附加费?liq. liquid 液体(的)?Lkg/Bkg leakage & breakage 漏损与破损?LLO Lift on / Lift off 上下车费?LNG Liquefied natural gas 液化天然气?LO/LO lift on,lift off 吊上吊下,吊装?LOA LENGTH OVER ALL 船舶全长?load loading 装货?LOADREADY READY FOR LOADING,READY TO LOAD 已备妥,可装货? loc. local;location 当地;位置?Long.,long longitude 经度?LPG Liquefied petrochemical gas 液化石油气?LSD loading,storage and delivery charges 装船,仓储和交货费用?LT LINER TERMS 班轮条款?LT letter telegram 书信电报?LTA lighter than air system(airships)?LTD LIMITED 有限(公司)?ltge lighterage 驳运费?ltr. lighter 驳船?lump lump sum 包干金额,总数?M minimum(rate classification) 最低(运费)?m metre(s) 米?M. MEASUREMENT 按货物的体积计算运价?M.H. Merchants Haulage 商船运输?M.S. MOTOR SHIP 内燃机船?M/R mates receipt 大付收据?M/R,M.R. MATES RECEIPT 大副收据?M/S Motor ship 内燃机船?M/T,MT METRIC TON OR MOTOR TANKER 公吨或内燃机油轮? M/V Motor Vessel 内燃机船?M+R maintenance and repair(centre) 维护修理?m3 cubic metre(s) 立方米?MACH modular automated container handling?MAF Manifest Amendment Fee 舱单改单费?MAWB Master Air Waybill 总运单(空)?MAX MAXIMUM,THE MOST 最大(多)?Mdse merchandise 商品?MFN Most Favoured Nation 最惠国?MIN MINIMUM,THE LEAST 最小(少)?MOLOO MORE OR LESS AT OWNERS OPTION 溢短装由船东选择? MOLSO MORE OR LESS AT SELLERS OPTION 溢短装由卖方选择? msbl missing bill of lading 丢失提单?msca missing cargo 灭失货物?MT motor tanker 内燃机油轮?MTD multimodal transport document 多式联运单证?MTO multimodal transport operator 多式联运经营人?MTON MEASUREMENT TON 尺码吨?MV MOTOR VESSEL 内燃机船?N normal(rate classification) 普通货(运价)??value?无商业价值?不另说明?不管卸货?不迟于,不晚于?不另编号?未另列出?未列名?未列名??value?declared 未声明价值?N/M NO MARK 无麦头?n/n non-negotiable 不可转让的?N/O no order 无定单?N/R NOTICE OF READINESS 装卸准备就绪通知书?NAABSA not always afloat but safely aground 不经常漂浮但安全坐浅? NAOCC Non Aircraft Operating Common Carrier 无航空器公共承运人?NAWB Neutral Air Waybill(forwarders Air Waybill) 货运代理人空运分运单? NGO non governmental organization 非官方组织?NOR NOTICE OF READINESS 装卸准备就绪通知书?NR NUMBER 数字,号码?NRT NET REGISTER TONNAGE 净登记吨?NT.WT. NET WEIGHT 净重?NVO (NVOCC) Non-Vessel Operating Common Carrier 无船承运人?NVOCC NON-VESSEL OPERATIONS COMMON CARRIER 无船公共承运人? 燃油附加费?O.R. owners risk 船舶所有人或货主承担风险?破损风险由货主承担?损失风险由货主承担?火灾风险由货主承担?经公路或铁路?O/D on deck 甲板上?OAC Origin Accessory Charge 始发港杂费?OBL Ocean Bill of Lading 海运提单?OBO Ore Bulk Oil(carrier) 矿石,散货和石油多用途船?Oc.B/L Ocean Bill of Lading 海运提单?OCB OCEAN FRT. BOX 海运费?OCC Ocean Common Carrier 远洋公共承运人?OCP OVERLAND COMMON POINTS 内陆共同点?ODS operating differential subsidy 营差别补贴?OFA ocean freight agreement 海运运费协议?OIB Original Inland (Box) 启运港内陆附加费?ORC Original Receiving Charge 启运港接货费?OT open top(container) 开顶式集装箱?OTI 远洋运输中介公司?OWS OVERWEIGHT SURCHAARGE 超重附加费?P & D pick up and delivery?P & I CLUB PROTECTION AND INDEMNITY CLUB 船东保赔协会?P.& I. Protection and Indemnity Association 船东保赔协会?P.& I. clause clause Protection and Indemnity clause 保护和赔偿条款?P.& I.Club Protection and Indemnity Club 船东保赔协会?P.& L. profit and loss 收益和损失?p.a. per annum(per year) 每年?P.A. particular average 单独海损?由代理支付?每立方英尺...镑?P.chgs particular charges 特别费用(保)?p.d. partial delivery 部分交付?每天每舱口(租船)?P.L. partial loss 部分损失(保)?邮政信箱?交货时付讫?p.t. per ton 每吨?按吨计?P/C Paramount Clause 最重要条款?P/N promissory note 期票;本票?PA PARTICULAR AVERAGE 单独海损?Para paragraph 文章的段或节?payt. payment 支付,赔偿?PCF Panama Canal Transit Fee 巴拿马运河费?PCS Port Congestion Surcharge 港口拥挤费?PCT PERCENT 百分比?pd. paid 已付款?PDPR PER DAY OR PRORATA 按天计算,不足一天者按比例计算? PENAVICO CHINA OCEAN SHIPPING AGENCY 中国外轮代理总公司? PKG PACKAGE 包装?pkge package 包装?PLP parcel post 包裹邮寄?PLTC port liner term charges?PM POST MERIDIEM=AFTERNOON 下午?pmt prompt 即时的?POD port of discharge 卸港?POL port of loading 装港?POR port of refuge 避难港?pp/ppd prepaid/prepaid 预付?PRO RATA IN PROPORTION 按比例(计算)?PROX PROXIMO,NEXT MONTH 下个月?PSC Port Service Charge 港口服务费?PSS Peak season surcharge 旺季附加费?pt/dest port of destination 目的港?pt/disch port of discharge 卸港?PTL partial total loss 部分和全部损失?ptly pd partly paid 已付部分款?PWWD PER WEATHER WORKING DAY 每晴天工作日?Q Quantity (rate classification) 数量?数量由船长决定?q.v. quod vide(which see) 见本项?Qn Quotation 引述,引用?RF Refrigerated Container 冷藏箱?RSC Restowage Charge 翻舱费?S surcharge(rate classification) 附加费?s & c shipper and carrier 托运人与承运人?S.& F.A. shipping and forwarding agent 运输代理?S.d. small damage 小量损坏?s.l.& c. shippers load and count 发货人装船和计数?S.L./N.L. ship lost or not lost 船舶灭失与否?船舶所有人的义务?平均分担单独海损?S/C surcharge 超载?S/D sailing date 启航日期?S/d sight draft 即期?S/O SHIPPING ORDER 装货单,关单,下货纸?S/P STOWAGE PLAN,CARGO PLAN 货物积载图,船图?S/S steamship 汽船,轮船?SB SAFE BERTH 安全泊位?SCF(C) Suez Canal Transit Fee (Charge) 苏伊士运河费?SCR specific commodity rate 列名商品费率?SDR Special Drawing Rights 特别提款权?SDT Shipper Declatation for the transport of dangerous goods (FIATA FORM)?SHEX SUNDAYS,HOLIDAYS EXCEPTED 星期日和节假日除外?SHEX sundays and holidays excluded 星期天和例假日除外?SHINC SUNDAYS,HOLIDAYS INCLUDED 星期日和节假日包括在内?SINOCHART CHINA NATIONAL CHARTER CORPORATION 中国租船公司?SINOTRANS CHINA NATIONAL FOREIGN TRADE TRANSPORTATION CORP. 中国对外贸司?SLI shippers letter of instruction 发货人说明?SOONEST AS SOON AS POSSIBLE 尽快,尽速?SOS SAVE OUR SHIP,A MESSAGE FOR HELP (船舶遇难)呼救信号?SPACETONS MEASUREMENT TONS INCLUDING BROKEN STOWAGE SPACE 包括亏舱在SPS Shanghai Port Surcharge 上海港附加费?SPS Shanghai Port Surcharge 上海港附加费?sq.cm(s) square centimtre(s) 平方分米?sq.in(s) square inch(es) 平方英寸?SRCC STRIK,RIOTS AND CIVIL COMMOTION 罢工,暴乱,内哄(险)?SS STEAM SHIP 蒸汽机船?stvdrs stevedores 码头装卸工人?sub L/C subject to letter of credit being opened 按照开立的信用证?sub licence subject to licence being granted 按照批准的许可?SUB-CHARTERER THIRD OWNER OF THE SAME VESSEL 再租人,三船东?SUBLET TRANSFER THE CHARTERSHIP 转租?SUBS SUBSTITUTE 代替?SWAD SALT WATER ARRIVAL DRAFT 抵港海水吃水?SWDFT SALT WATER DRAFT 海水吃水?T.A. telegraphic address 电报挂号?航次期租船?T.D. TWEENDECK 二层柜?卸货时间?收到时间?T/C TIME CHARTER 期租?T/T TURBINE TANKER OR TELEGRAPHIC TRANSFER 汽轮机油轮或电汇?TACT the air cargo tariff(IATA) 空运货物费率?TB TO BE 将要...?TBL through bill of lading 联运提单?TBL Through Bill of Lading 全程提单?TBN to be named 待指定?TBN TO BE NOMINATED 待派(船),待指定?TC traffic conference area(IATA)?TC TYPE CRANES 单杆吊(船舶吊杆类型)?TCS Temperature Control Surcharge 控温附加费?TD time of departure 开航时间?TD TYOE DERRICKS 双杆吊(船吊类型)?TDC T-document fees 中转单证费?TDO telegraph delivery order 电报交货单?TDY TODAY 今天?TEEM Trans-Europe-Express Merchandises (rail service) 横贯欧洲快运货物?TEU TWENTY EQUIVALENT UNIT 20标准集装箱?TIB Temporary Importation Bond 临时进口保证金?TIF international transit by rail 国际铁路运输?TIR Customs Convention on the intl transport of goods under cover of TIR carnets(intl road transpor TKS THANKS 感谢?TL Total Loss 全损?TLX TELEX 电传?tnge Tonnage 吨位?TOFC Trailer on board flatcar 平板车载运带拖车的集装箱?TOT time of transmission 传递时间?tot. total 总共?TOW tier on weight 贸易条款?TPI TON PER INCH 每一英寸载重吨?TPNP THEFT,PILFERAGE AND NONDELIVERY 偷,盗和提货不着(险)?TRC Terminal Receiving Charge 码头接运费?TRS Transpacific Revenue Surcharge?TWCS U.S. West-coast Congestion Surchage 美西疏港费?u.c. usual conditions 通常情况下?U.D. under deck 下层甲板?U.DK. Upper deck 上层甲板?U/w Underwriter 保险人?ULCC ULTRA-LARGE CRUDE CARRIER 特大型油轮?ULD unit load device(aircraft) 成组货载装置?ULT ULTIMO,LAST MONTH 上月的?UU UNLESS USED 除非使用?V VOYAGE 航程,航次?V.C. vessels convenience 方便船?v.v. vice versa 反之亦然?V/C VOYAGE CHARTER 程租船?val.?Value?价值?VAT?value?added tax 增值税?VEN Ventilated 通风?Ves. Vessels 船舶?VIC Very Important Cargo 非常重要货物?VIO Very Important Object 非常重要目标?VLBC VERY LARGE BULK CARRIER 大型散装船?VLCC VERY LARGE CRUDE CARRIER 大型油轮?VOCC Vessel Operating Common carrier 有船公共承运人?W GROSS WEIGHT 毛重?W.A. with average (Institute Cargo Clause) 承保单独海损,水渍险??w.c. with costs 付费的?无论清关与否?通过有效形式?W.P. WERTHER PERMITS 如果气候条件许可?担保单独海损?W.R. Warehouse Receipt 仓库收据?战争险?W/B Way-bill 运货单?W/d working day 工作日?W/M GROSS WIGHT OR MESUREMENT 按货物重量与体积分别计算,按高者收费? W/O.w/o without 没有,不?w/t weight tons 重量吨?w/v weight/volume 重量或体积?WA WITH PARTICULAR AVERAGE 水渍险?wdt/wth width 宽度?WG working group 工作小组?whf wharfage 码头搬运费?Whse Warehouse 仓库?WIBON WHETHER IN BERTH OR NOT (船舶)不管靠泊与否?WICCON WHETHER IN CUSTOMS CLEARANCE OR NOT (船舶)不管通关与否? WIFPON WHETHER IN FREE PRATIQUE OR NOT (船舶)不管检疫与否?WIPON WHETHER IN PORT OR NOT (船舶)不管抵港与否?wk. Week 周,星期?WOG WITHOUT GUARANTEE 没有保证?WP weather permitting 天气许可的条件下?WPA WITH PARTICULAR AVERAGE 水渍险?WRITING WE(I) SHALL WRITE TO YOU ABOUT IT LATER 详情函告?WRS War Risk Surcharge 战争风险附加费?WT WEIGHT 重量?wt. Weight 重量?WTON WEIGHT TON 重量吨?WTS WORKING TIME SAVED 节省的工作时间?WTS Winter Surcharge 冬季附加费?WTSBENDS WORKING TIME SAVED AT BOTH ENDS 装卸港均以节省的工作时间计算(速遣WW warehouse warrant 仓库栈单?ww world-wide 世界性的?WWD WEATHER WORKING DAY 晴天工作日?WWDSHEX WEATHER WORKING DAY SUNDAYS,HOLIDAYS EXCEPTED 晴天工作日,星日除外?WWDSHING WEATHER WORKING DAY SUNDAYS,HOLIDAYS INCLUDED 晴天工作日,星日包括在内?x l & u l exclusive of loading and unloading 不包括装卸?x pri without privileges 无例外?X,X. extra 额外的?xp express paid 快递费付讫的?YAS (Japanese)Yen Adjustment Surchae 日元币值调整附加费?AIR DRAFT LENGTH BETWEEN WATER LEVEL AND VESSELS RAIL 水平面至船弦的高度Add-on .tariff(also proportional rate or arbitrary in US) 费率标记(在美国也指按比例或仲裁决定) BALTIME UNIFORM TIME CHARTER 统一定期租船合同,巴尔的摩期租合同?BREAKDOWN AN ITEMIZED ACOUNT OF...ITEM BY ITEM 细目分类?Bags/Bulk part in bags,part in bulk 货物部分袋装,部分散装?without privileges 无例外?Foreign Trade 对外贸易?Entrepot Trade ( F。

医疗器械问卷调查表

附件V（生产质量保证体系）
Annex VI (Product Quality Assurance)
附件VI（产品质量保证体系）
Annex V (For sterility of Class 1 products)
附件V（第一类无菌产品的全面质量保证体系）
Annex V (For sterility under Article 12)
Annex IV (EC Verification)
附件IV（EC验证）
第3页共7页
QUESTIONNAIRE – MEDICAL DEVICES
Please define proposed scope of SGS registration for these standards, if applicable.
existing certification please use SGS Notification forms. 如果您已经是SGS的客户只需列明现在增加的认证申请。对于范围的扩展认证请用SGS的表格
3. Please return in electronic format or hard copy to your local SGS certification office as shown
Certification 认证
Please indicate with X the certification you wish to achieve with SGS 请用X标明您希望SGS提供的认证
ISO 9001: 2000, and please give details of any intended exclusions (clause numbers) ISO9001:2000认证，并给出想要删减的详细资料（标准的条款号）

出国疫苗证明中英文版

出国疫苗证明是出国前必须携带的证明文件，它既代表着学生回国时的健康状况，又表明了学生具备安全出国的能力。

本文将介绍出国疫苗证明的英文版内容以及出国前必备的各项疫苗，帮助那些准备出国留学的学生来前置准备出国必要的一切。

出国疫苗证明英文版主要起证明学生入境前已积极接种全面有效疫苗的作用，表明学生勤洗手、健康出行的意识。

通常的出国疫苗证明模板包括个人信息部分（名，姓，性别，出生日期）, 保护个人免遭感染, 接受疫苗时间以及疫苗名称，免疫医生和证书签发医院名称，等等。

出国前学生所需接种的疫苗，除了国际推荐的六种重要的疫苗：A群球菌疫苗、乙肝疫苗、流感疫苗、麻疹水痘混合疫苗、预防腮腺炎疫苗以及肺炎球菌疫苗，还有其他的几种根据实际情况和目的地的疫苗，如新型冠状病毒肺炎（ COVID-19 ）、伤寒疫苗、狂犬疫苗等。

因此，准备出国留学的学生应当在出国前做好充分的诊断，向医生了解当地推荐的疫苗，以确保安全出行，同时注意行前抗菌素检查，以预防病菌感染。

另外，准备出国的学生还应多关注官方的出国信息，查看护照要求，以及到达目的地可能需要携带的材料，最后仔细核对自己携带的出国疫苗证明英文版，确保出国留学无任何问题。

Vaccination Certificate for OverseasVaccination Certificate for overseas is a necessity document for people whoare planning to travel abroad. It not only represents the health condition of a person before returning, but also a proof of the ability of the particular person to go overseas safely. In this article, we are going to talk about the details in the English version of the Vaccination Certificate, as well as all the necessary vaccines for the overseas travel.The main purpose of the English version of the vaccination certificate is to remind the reader that the international passengers have been vaccinated effectively. It usually contains personal information (name, tax, gender and date of birth), protection against infection, date of vaccine and name of vaccine, physician’s name and name of the issuing hospital, etc.Apart form the six key vaccines recommended by the World Health Organisation, which include, A Streptococcus polysaccharide vaccine, Hepatitis B vaccine, Influenza virus vaccine, Measles, Mumps and Rubella (MMR) vaccine, Meningococcal polysaccharide vaccine and Pneumococcal polysaccharide vaccine. There are some other vaccines which depend on the destination or situation of the overseas traveler, such as the new coronavirus (COVID-19), Anthrax vaccine, Rabies vaccine, etc.Therefore, it is inevitable for the student who is ready to travel overseas to do a full investigation of the recommended vaccines in the destination according to the information from the doctor in order to ensure the journey will be free of any contamination. Besides, it is fundamental to stay informed about the official news about the destination, check passport requirements, and materials needed to enter the destination. Last but not least, look through the English version of the Vaccination Certificate and make sure it meets the requirements of the destination.。

菲律宾出口运送费用表说明书

(Rates exclude special fees)11All rates are exclusive of all applicable tax. For special fees, please refer to the Surcharge and Other Information page for details. Remarks:-Services are provided on a contract-only basis. Please contact our Customer Service team for details.-Each package of a FedEx IPD shipment can measure up to 108" / 274cm in length, 70" / 178cm in height, and 130" / 330cm in length plus girth. -No fuel surcharge will be applied to shipments paid by Philippines local payers.(Rates exclude special fees)11All rates are exclusive of all applicable tax. For special fees, please refer to the Surcharge and Other Information page for details. Remarks:-Services are provided on a contract-only basis. Please contact our Customer Service team for details.-Each package of a FedEx IED shipment can measure up to 108" / 274cm in length, 70" / 178cm in height, and 130" / 330cm in length plus girth. -No fuel surcharge will be applied to shipments paid by Philippines local payers.(Rates exclude special fees)11All rates are exclusive of all applicable tax. For special fees, please refer to the Surcharge and Other Information page for details.Remarks:-Services are provided on a contract-only basis. Please contact our Customer Service team for details.-Each package of a FedEx IDF shipment can measure up to 119" / 303cm in length, 70" / 178cm in height, and 300" / 762cm in length plus girth.-A minimum of 137kg rate charge shall apply in case the total weight of an IDF shipment is less than 137kg. Please contact our Customer Service team for details. -No fuel surcharge will be applied to shipments paid by Philippines local payers.PhilippinesZONE TABLE:=International Priority DirectDistribution=International Priority DirectDistribution Freight=International Economy DirectDistribution1. Find the zone for your destination in the zone table.2. Determine your total shipment weight (round up to the next-higher kilogram).3. Multiply the per-kilogram rate shown in the rate table by the total shipment weight.4. Multiply the per-address charge shown in the rate table by the number of addresses in your shipment.Fuel Surcharge No fuel surcharge will be applied to shipments paid by Philippines local payers.Special Handling FeesAddress Correction:1USD 13.60 per delivery address Third Party Billing Surcharge:2.5% of total shipment charges Saturday Delivery:1USD 18.10 per delivery addressPiece Count Verification:2USD 39.00 per package or USD 0.48 per kg, whichever is greater Appointment Delivery:2USD 34.70 per delivery address*Out of Pickup Area Surcharge (OPA):USD 25.17 per shipment or USD 0.43 per kg, whichever is greater *Out of Delivery Area Surcharge(ODA):USD 25.17 per delivery address or USD 0.43 per kg, whichever is greater* FedEx imposes a surcharge for shipments to areas outside those in which its own couriers pick up and deliver cargo (OPA and ODA areas). A list of ZIP and postal codes where these surcharges apply for DirectDistribution products is available here.Residential Delivery Surcharge:USD 4.10 per IPD delivery address or USD 128.80 per IDF delivery address (applicable to US & Canadadestinations only). If the ODA Surcharge is applied to a shipment, the Residential Delivery Surcharge will not apply.Inaccessible Dangerous Goods:USD 83.00 per shipment or USD 1.10 per kg, whichever is greater. A minimum billable weight may apply.Please contact our Customer Service team for details.Dry Ice Surcharge:USD 5.90 per shipment. If a shipment contains both dry-ice and dangerous goods (accessible or inaccessible),only dangerous goods surcharge applies, and dry-ice surcharge is not applied.Priority Alert - Package:USD 62.50 per shipment or USD 2.50 per kg, whichever is greater, for IPD Priority Alert Plus - Package:USD 75.00 per shipment or USD 3.75 per kg, whichever is greater, for IPD On-demand Care - Package:USD 125.00 per shipment or USD 5.50 per kg, whichever is greater, for IPDDuty and Tax:If duties and taxes are levied on a shipment and FedEx pays them on behalf of the party responsible forpayment, then that party must reimburse FedEx for the duties and taxes themselves, plus a FedEx surcharge that is based upon the type of shipment and its destination. Please contact our Customer Service team for details.Declared Value Charge for Carriage:Liability of Fedex for loss, damage or delay of your shipment is limited to the greater of about USD20.00 per kilogram or USD100.00 per shipment. The exact limitation may be expressed in Special Drawing Rights or local currency and the exact amount will vary depending upon the country/ territory of origin and currency.If you desire that FedEx assumes liability for a greater percentage of the actual cargo value, then you must declare the value for carriage on your air waybill and pay a “declared value surcharge”. The “declared value surcharge” for Export shipments in Philippines is equal to USD 2.39 per USD 100.00 (or fraction thereof) by which the declared value for carriage exceeds the greater of: (i) USD 100.00 or (ii) USD 9.07 per pound. The following maximum declared value for carriage will apply. Please contact our Customer Service team for details.Maximum Declared Value for Carriage (may vary by destination)International Priority DirectDistribution/Economy DirectDistribution (IPD/IED):International Priority DirectDistribution Freight (IDF):Shipments containing items of extraordinary value such as artwork, antiques, glassware, jewelry,precious metals, furs, etc.:USD 50,000.00 (or equivalent value in local currency)USD 100,000.00 (or equivalent value in localcurrency)USD 1,000.00 or USD 20.00 per kg, whichever isgreaterFootnotes1This surcharge is applicable to IPD and IDF only.2 This surcharge is applicable to IDF only.Weight Information Total shipment weight is unlimited. The maximum weight per package may be adjusted. Please contact ourCustomer Service team or Sales team for details.Rates are calculated on the total weight of all packages on one international air waybill. Any fraction of akilogram is rounded up to the next higher weight break. Such rounding may cause a variance in dimensionalweight (volumetric weight) calculations. Please note that the rates stated on FedEx's invoice shall be the finaland official rates.Additional charges may be assessed for shipments below a certain weight density. The dimensional weight(volumetric weight) (in kg) of an IPD/IDF/IED shipment is calculated as follows. Please contact our CustomerService team for details.Length x Width x Height (centimetres or inches)5,000 for centimetres or 305 for inchesShipments in FedEx packaging may be subjected to dimensional weight pricing.Miscellaneous Information• These rates, valid until further notice, are only available to customers who remain in good standing with their FedEx account and settle their invoice promptly.• FedEx reserves the right at any time to amend, modify, or discontinue discounts without prior notification.• As noted above, various surcharges and fees may be imposed on your shipment in addition to the prices noted on this ratesheet. By tendering your shipments to FedEx, you agree to pay the surcharges as determined by FedEx.• Please note that your shipment is governed by several documents: your discount-pricing letter agreement with FedEx (if applicable), the Conditions of Contract printed on the FedEx Air Waybill for your shipment, the FedEx Service Guide, the FedEx Standard Conditions of Carriage, and/or FedEx International Terms and Conditions in effect at the country/ territory of origin. These documents provide for the above surcharges, fees, and other important terms that you should review. If you need assistance or desire additional information, please contact our Customer Service team.• All rates are exclusive of all applicable tax. An export processing charge may be levied by the origin country/ territory, Philippines, and if so levied, will be billed to the shipper.• For Address Correction, if the package is being rerouted to a different Country/ Territory, City or Province, a new shipment fee may apply.• Total shipment charges includes transportation charges, surcharges and additional fees; but does not include duties, taxes and ancillary clearance service fees. The Third Party Billing Surcharge applies when an account unrelated to the shipper, as solely determined by FedEx, is billed as a third party for the shipment.FedEx Rate Sheet Terms and Conditions1. Contract-Only Basis. Services are provided on a contract-only basis. Please contact our Customer Service team for details.2. Maximum Package Size. Each package of a FedEx IPD / IDF / IED shipment can measure up to:- IPD shipment: 108" / 274cm in length, 70" / 178cm in height, and 130" / 330cm in length plus girth.- IDF shipment: 119" / 303cm in length, 70" / 178cm in height, and 300" / 762cm in length plus girth.- IED shipment: 108" / 274cm in length, 70" / 178cm in height, and 130" / 330cm in length plus girth.3. IDF Minimum Charge. A minimum of 137kg rate charge shall apply in case the total weight of an IDF shipment is less than 137kg. Please contact our Customer Service team for details.For InquiriesCustomer Support: https:///en-ph/customer-support/write-to-fedex.html。

糖尿病申请特殊医保流程

糖尿病申请特殊医保流程英文回答：To apply for special medical insurance for diabetes, there are a few steps that need to be followed. Firstly, it is important to gather all the necessary documents and information. This includes medical records, doctor's diagnosis and recommendations, as well as any otherrelevant documents that prove the presence and severity of diabetes. Additionally, it is crucial to have all personal identification documents such as ID cards, proof of address, and insurance information ready.Once all the required documents are collected, the next step is to fill out the application form for specialmedical insurance. This form can usually be obtained from the local healthcare authority or insurance provider. It is important to fill out the form accurately and provide all the requested information. Any missing or incorrect information may lead to delays or rejection of theapplication.After submitting the application form, it is necessary to wait for the approval process to be completed. This may involve a review of the submitted documents and a medical assessment to determine the eligibility for special medical insurance. The timeframe for the approval process may vary depending on the healthcare system and the specific requirements for diabetes coverage.Once the application is approved, it is important to review the terms and conditions of the special medical insurance coverage. This includes understanding the extent of coverage, any limitations or exclusions, as well as the procedures for making claims and accessing healthcare services. It is advisable to seek clarification from the insurance provider if there are any uncertainties or concerns regarding the coverage.In order to maintain the special medical insurance coverage for diabetes, it is important to comply with the requirements and guidelines set by the insurance provider.This may include regular check-ups, adherence to prescribed medications and treatment plans, as well as lifestyle modifications to manage diabetes effectively. Failure to comply with these requirements may result in the termination or modification of the insurance coverage.Overall, the process of applying for special medical insurance for diabetes involves gathering necessary documents, filling out the application form accurately, waiting for the approval process, reviewing the coverage terms and conditions, and maintaining compliance with the insurance provider's requirements. It is essential to be well-prepared and informed throughout the process to ensure a smooth application and ongoing coverage.中文回答：申请糖尿病特殊医保有几个步骤需要遵循。

办理熏蒸证明有什么作用

办理熏蒸证明有什么作用熏蒸证明英语范本Amount of Credit in US Dollars : ________________(SayUSD_______________)Partial Shipment: Allowed Shipment From: Tianjin Seaport Shipment To: Vishakapatnam / Paradip / Gangavaram Seaport, India Latest Shipment Date: ________________ Description of Goods:________________ (state Goods description)Size (in centimeters):________________ Quantity (in Metric Tonnes): _____________ Delivery: FOB Tianjin Seaport INCOTERMS 2000 Basis Documents Required:1 Beneficiary’s Commercial Invoic e; and2 Full set of Clean-On-Board Bill of Lading issued to order; and3 Test Certificates from the Manufacturer; and4 Certificate of Origin; and5 Detailed Packing List indicating details of the contents; and6 Copy of Fax & e-mail from the Beneficiary to MIPP INTERNATIONAL LTD. at the e-mail________ and FaxNo. :___________within______ working days after Clean-On-Board Bill of Lading, advising the name of the vessel, Bill Lading No. & date, details of the packages and quantity plus weight, and other relevant details of shipment; and7 Fumigation Certificate for any shipment package which is packed with wooden material8 Bank Charges:a. All bank charges incurred inside China shall be borne and paid for by the Beneficiary.b. All bank charges incurred outside China shall be borne and paid for by the Applicant.9. Period for presentation: within ______ days from the date of Bill of Lading.Advising through: _______________Reimbursement instructions:。

Osprey Transporter Series Owner's Manual

TRANSPORTER SERIESTRANSPORTER 130TRANSPORTER 95TRANSPORTER 65TRANSPORTER 40Welcome to Osprey. We pride ourselves on creating the most functional,durable and innovative carrying product for your adventures. Please refer tothis owner’s manual for information on product features, use, maintenance, customer service and warranty.OWNER'S MANUALSHARED FEATURES1 Dual-zippered 3D end pockets with overlapping rain flaps for quick access to smaller items2 Four burly webbing grab handles3 Eight web lashing points for securing duffel or attaching gear 4Large lockable U-zip access to main compartment5 Weather-protected main compartment zip path with overlapping rain flaps6 Stowaway contoured harness and yoke for comfortable backpack carry7 D-ring attachments for adding a shoulder strap +Internal zippered mesh side panel pocketFABRICMAIN 780D Packcloth Double Coated TPUACCENT 360/400D Two Tone Packcloth Double Coated TPUBOTTOM 780D Packcloth Double Coated TPU7241635TRANSPORTER 130 SPECSCubic Inches 7933Liters 130Pounds 4.06Kilograms 1.84 Inches 32h x 18w x 15d Centimeters 81h x 46w x 37dTRANSPORTER 95 SPECSCubic Inches 5797Liters 95Pounds 3.49Kilograms 1.59 Inches 27h x 15w x 13d Centimeters 69h x 37w x 34d1TRANSPORTER 65SPECS Cubic Inches 3967 L iters 365Pounds 3.10 Kilograms 1.41 Inches 24h x 14w x 13d Centimeters 60h x 36w x 32dTRANSPORTER 40SPECS Cubic Inches 2441L iters 40Pounds 2.67 Kilograms 1.21 Inches 21h x 12w x 11d Centimeters 53h x 31w x 27dUNIQUE FEATURES1 Shoulder strap includedUNIQUE FEATURES 1Shoulder strap included1CARRY1 STOWAWAY SPACERMESH HARNESS + Full yoke and contoured harness straps + Soft, breathable contact surface for comfort + Adjustable sternum strap with safety whistle + Adjustable load lifters transfer weight from harnessto hipbelt*Transporter 130 and 95 onlyPACK / RESERVOIR MAINTENANCEYour Osprey pack is an extremely durable product and is built for years of use. However, some basic pack maintenance will help ensure your pack lasts a lifetime.For complete instructions on cleaning your Osprey pack, visit:/PackTech/PackCare.OSPREY PACKSSTANDARD MAINTENANCE+ After each trip be sure to clean out your pack thoroughly.+ C lean the zippers regularly using mild soap, warm water and soft brush. This willhelp keep them in proper working condition.+ I f your pack is wet, hang it to dry out of direct sunlight.+ L oosen all the straps.+ W ash your pack if dirt, sweat, salt and stains have worked their way into fabrics,webbing or mesh.(Do not immerse travel packs in water with our HighRoad™ Wheeled Chassis.)WASHING YOUR PACKA E mpty the pack including any food, dirt or spilled contents.B I f your pack has a removable harness and hipbelt, remove them from the pack body.CD o NOT wash your pack in a washing machine. Clean your pack and componentsin a bathtub or large sink using a mild detergent and warm water.D A gitate the pack gently. Scrub the inside and outside of all compartmentsincluding the pockets with a soft brush.E C lean the zippers using a mild soap, warm water and a soft brush. Flush waterand soap through the buckles. Keeping dirt and debris out of the zippers and buckles will help keep them in proper working condition.F D rain the dirty water from the bathtub or sink and refill with cool clean non-soapy water. Rinse the pack thoroughly. Repeat this step as neccessary.G H ang your pack to dry outside or in a well ventilated area, out of direct sunlight.WHEELED TRAVEL LUGGAGE(Do not immerse travel packs in water with our HighRoad™ Wheeled Chassis.)A A fter each trip, e mpty the pack including any food, dirt or spilled contents.BC lean the zippers regularly using mild soap, warm water and soft brush. This willhelp keep them in proper working condition.C W ipe the exterior of the chassis with a damp cloth or sponge.D C lean the pack fabric by scrubbing stains and dirt with warm water, milddetergent and a soft brush or sponge.E U se a wet towel with clean non-soapy water to wipe away any soap residue onthe pack.F H ang your pack to dry outside or in a well ventilated area, out of direct sunlight.RECOMMENDED CLEANING PRODUCTSOsprey recommends Nikwax® products for pack care. Be sure to read label directions carefully before applying any product to your pack.Tech Wash® - Use this with warm water for washing and cleaning your packs or luggage.Tent & Gear Solar Proof® - Use this spray-on product to protect your packs from UV exposure and to improve water repellency.OSPREY RESERVOIRSRESERVOIR STANDARD MAINTENANCE+ R insing out your reservoir after each use should keep your reservoir fresh,especially when using sugary drink mixes.+ P eriodically use Osprey's Hydraulics™ Cleaning Tablets to clean your reservoir.+ I odine or other purifying tablets used in your reservoir will not affect the qualityof your reservoir. However these tablets may stain the reservoir over time.+ F reezing your reservoir will not effect the quality of the reservoir. However if thereservoir is filled with water, be aware that water expands when it freezes and can damage your reservoir if it is overfilled.+ D o NOT pour boiling water into the reservoir. This can damage the reservoir andwill void your warranty.+ W atch “Cleaning an Osprey Hydraulics™ Reservoir” video on Osprey PacksYouTube® page.CLEANING YOUR RESERVOIR (WITH OSPREY HYDRAULICS™ CLEANING TABLETS )A F ill reservoir with warm water. Do not use bleach or boiling water.B A dd one cleaning tablet to reservoir and close the cap.C L et tablet dissolve for 5 minutes with the reservoir laying on its back.D S hake the reservoir for 30 seconds to mix and spread the solution.E P inch the bite valve and squeeze the reservoir to remove air and fill thereservoir hose and bite valve with solution.F L et the reservoir sit for 15 minutes and then pour out solution.G R inse the reservoir and tube with clean cool water.H Hang your reservoir to dry in a well ventilated area.DEEP CLEANING YOUR RESERVOIR (WITH OSPREY HYDRAULICS™ CLEANING KIT )1 R inse out the reservoir and fill it with warm water and a mild dish detergent.Do not use bleach or boiling water.2 W ith the large cleaning brush from Osprey's Hydraulics™ Cleaning Kit scrub theinterior of the reservoir.3 R emove the hose from the reservoir and the bite valve from the hose and usethe small brush from Osprey's Hydraulics™ Cleaning Kit to scrub the interior of the hose.4 R emove the silicone bite valve cover and clean it and the bite valve with warmsoapy water.5 R inse the interior and exterior of the reservoir, hose and bite valve parts withcool clean water.6 L et the hose and bite valve dry in a well-ventilated area.7 I nsert Osprey's Hydraulics™ Cleaning Kit drying rack into the reservoir andhang to dry in a well ventilated area.For complete instructions on cleaning your Osprey reservoir watch,“Cleaning an Osprey Hydraulics™ Reservoir” at /ospreypacks.For more information on this product and others, pack care, how to pack your pack,our lifetime guarantee, or to contact Osprey Customer Service, visit .OWNER'S MANUAL。

【干货分享】史上最全的英国看病实用贴

【干货分享】史上最全的英国看病实用贴传闻中英国福利好，看病不用钱，就代表英国医疗体系比国内强一万倍吗？总有将要成为留学狗的亲问来英国要带什么，而学长学姐们给出来的答案一定会有：药。

然而来到国外后，小伙伴们却又经常抱怨英国的医疗系统，怀念国内医院的方便快捷。

其实英国的医疗保障体系，是一个预防为主、保障公民健康的体制。

真要得了急病，医疗体制的反应是“你急他不急”。

今天居哥给大家推一条“炒鸡”实用的看病指南，让你详细了解英国的医疗系统，不用再担心生病后如何看病。

在英国看病，最常听到的就是NHS和GP。

NHS就是National health service, 是每个英国公民和留学生都可以享受到的服务。

从2015年4月开始，英国政府决定：对来自欧洲以外（包括中国）前往英国时间超过六个月以上的所有公民收取每年200英镑的“医疗附加费“，以便享有使用NHS服务的权利，留学生可以打个75折，就是150镑。

这个费用在你签证的时候就被“硬性征收”了。

看GP也就是看医生，是指每个社区的General Practitioner。

但看GP需要提前预约，所以如果是感冒这种小病，居哥建议大家就多从国内带点药或者去boots买点阿莫西林自我痊愈就好了。

因为可能等你感冒好了还看不到医生，或者你约到医生，结果医生给你开几粒维生素这种坑爹的情况都是很常见的。

在国内，感冒这种小病也有分风寒感冒和热感，要对症下药。

但在国外，最常见的感冒药就是阿司匹林。

所以如果感冒有习惯喝小柴胡，999这些含有中药成分的冲剂，居哥建议大家还是从国内多带点以防万一吧~居哥这儿就来先给你萌科普一下看病常用名词：General Practitioner（GP）：社区医生GP Surgery：社区诊所Emergency & Accident（A&E）：急诊National Health Service（NHS）：英国国家医疗服务体系Preion：处方药（必须医生给处方才可以到药房获得）Pharmacy：药店还有更多看病用语，居哥统统给你萌准备好了！贴在文末啦已经～Step1——前戏！你该怎样注册GP如果大家住的是学生宿舍，那你可以直接去学校的Health center注册，如果是住在其它地方，亲们可以登陆NHS官网网站查看一下你的GP诊所在哪里。

UnitedHealth Premium程序的州特定流程指南说明书

The UnitedHealth Premium® program provides physician designations based on quality andcost-efficiency criteria to help members make more informed choices about their medical care. Physicians may also use these designations when referring patients to other physicians and to support their efforts to provide quality and cost-efficient care to their patients.The following states have requirements governing physician measurement programs that are different from other standard UnitedHealth Premium program processes. In these states, the Premium program may follow different or additional processes for physicians who are evaluated by the program.CaliforniaConsistent with Section 1367.49 of the Health and Safety Code and Section 10133.64 of the Insurance Code, please note the following and, if you choose to do so, take the following action.Per Section 1367.49(f) of the Health and Safety Code and Section 10133.64(f) of the Insurance Code, if you wish to include a link to your own website with a response to your designation in our posting, please provide us the link through the Contact Premium page: >Help and Support > Contact Premium. Colorado and TexasPhysicians may request a reconsideration of their UnitedHealth Premium designation, including a meeting by teleconference or in person. To arrange a meeting, please send us a request through the Contact Premium page: > Help and Support > Contact Premium.Important notes about the UnitedHealth Premium programThe information from the UnitedHealth Premium program is not an endorsement of a particular physician or health care professional’s suitability for the health care needs of any particular member. UnitedHealthcare does not practice medicine or provide health care services. Physicians are solely responsible for medical judgments and treatments supplied. A “Premium Care Physician” or “Quality Care Physician” designation does not guarantee the quality of health care services members will receive from a physician and does not guarantee the outcome of any health care services members will receive.PCA-1-22-01766-UHN-WEB_06032022Likewise, the fact that a physician has a “Not Evaluated for Premium Care” or a “Does Not Meet Premium Quality Criteria” designation does not mean that the physician does not provide quality health care services. All physiciansin the UnitedHealthcare network have met certain minimum credentialing requirements. Regardless of whethera physician has received a Premium Care Physician designation, members have access to all physicians in the UnitedHealthcare network, as further described under the member’s benefit plan.The designation of “Not Evaluated for Premium Care” is given when a physician does not practice in a specialty thatis evaluated by the Premium program, or when a physician’s evaluation is in process. It is also given when a physician does not have enough health plan claims data to be evaluated, but it is not an indicator of the total number of patients treated by the physician or the number of procedures performed by the physician.Rather, it reflects the statistical requirements of the Premium program, which includes only health plan claims associated with specific Premium program measures and relevant to the physician’s specialty. In some cases, there may not be enough data to complete the analytic process from a statistical standpoint.UnitedHealthcare informs members that designations are intended only as a guide when choosing a physician and should not be the sole factor in selecting a physician. As with all programs that evaluate performance based on analysis of a sample, there is a risk of error. There is a risk of error in the claims data used in the evaluation, the calculations used in the evaluation, and the way the Premium program determined that an individual physician was responsible for the treatment of the patient’s condition. Physicians have the opportunity to review this data and submit a reconsideration request.UnitedHealthcare uses statistical testing to compare a physician’s results to expected or normative results. There is a risk of error in statistical tests when applied to the data and a result based on statistical testing is not a guarantee of correct inference or classification. We inform members it is important they consider many factors and information when selecting a physician. We also inform our members that they may wish to discuss designations with a physician before choosing him or her or confer with their current physician for advice on selecting other physicians.The information contained in this State-Specific Processes document is subject to change.UnitedHealth Premium program | 9700 Health Care Lane, MN017-W700, Minnetonka, MN 55343Insurance coverage provided by or through UnitedHealthcare Insurance Company, All Savers Insurance Company, Oxford HealthInsurance, Inc. or their affiliates. Health Plan coverage provided by UnitedHealthcare of Arizona, Inc., UHC of California DBAUnitedHealthcare of California, UnitedHealthcare Benefits Plan of California, UnitedHealthcare of Colorado, Inc., UnitedHealthcareof Oklahoma, Inc., UnitedHealthcare of Oregon, Inc., UnitedHealthcare of Texas, LLC, UnitedHealthcare Benefits of Texas, Inc.,UnitedHealthcare of Utah, Inc. and UnitedHealthcare of Washington, Inc., Oxford Health Plans (NJ), Inc. and Oxford Health Plans(CT), Inc. or other affiliates. Administrative services provided by United HealthCare Services, Inc., OptumRx, OptumHealth CareSolutions, LLC, Oxford Health Plans LLC or their affiliates. Behavioral health products are provided by U.S. Behavioral Health Plan,California (USBHPC) or its affiliates.PCA-1-22-01766-UHN-WEB_06032022© 2022 United HealthCare Services, Inc. All Rights Reserved.。

赴美手续常用词汇详解

赴美手续常用词汇详解Admission Number(准许入境编号)：表I-94上所用编号(在F-1或M-1非移民签证的情况下，则是I-20 ID印件上所用编号)，供移民归化局(INS)查询此人时备用。

也称“身份编号”(Identification Number)。

Alien Registration Number(外侨登记号码)：简称“A”号码(“A”Number)。

本来是美国政府给予移民的身份编号(Identification number)，在某些情况下，由美国移民归化局斟酌决定，这种登记号码也可能给予非移民学生和交流学者。

不过，多数持有F-1、J-1和M-1签证留学美国的学生没有“A”号码。

“Arrival/Departure record”(Form I-94)(表I-94，入境-出境记录)：移民归化局文件，在美国入境地点签发，作为外国国民合法进入美国的证明。

表上明确注明证件持有者许可在逗留的期限，或是确定一个固定的“截止日期”(expiration date)，或是注上“D/S”字样。

“D/S”意为“身份有效期”(duration of status)，允许证件持有者在美国逗留到达成业经批准的目的为止。

“Certificate of Compliance”(守法证书)：付税情况审查记录文件，签发给离境外国国民，以证明当事人业已付清全部所得税。

在一般情况下，F-1、J-1和M-1非移民签证的持有者需要守法证书。

守法证书也称“离境签证”(Exit Visa)或“离境许可证”(Sailing Permit)。

“Certificate of Eligibility”(身份合格证书)：即表I-20 A-B、表I-20 M-N或表IAP-66。

表I-20A-B和表I-20 M-N由同意录取该外国学生为正规全日制学生来美学习的得到承认的美国高等院校、职业学校或其他非学术性院校签发。

表IAP-66(交流学者身份合格证)则由组织该项交流活动的单位或同意其进入该校的美国高等院校签发。

购买疫苗的合同范本英文

购买疫苗的合同范本英文Vaccine Purchase ContractThis Vaccine Purchase Contract (the "Contract") is made and entered into on [date] and between:Buyer:Name: [Buyer's Name]Address: [Buyer's Address]Contact Person: [Contact Person's Name]Telephone Number: [Telephone Number]E Address: [E Address]Seller:Name: [Seller's Name]Address: [Seller's Address]Contact Person: [Contact Person's Name]Telephone Number: [Telephone Number]E Address: [E Address]1. Product Description and SpecificationsThe Seller agrees to sell and the Buyer agrees to purchase the following vaccines:Vaccine Name: [Vaccine Name]Batch Number: [Batch Number]Expiry Date: [Expiry Date]Dosage and Form: [Dosage and Form]2. Quantity and PriceThe quantity of the vaccines to be purchased is [quantity], and the unit price is [price per unit]. The total purchase price is [total price].3. Delivery and ShippingThe Seller shall deliver the vaccines to the Buyer at the following address: [Delivery Address] on or before [delivery date]. The shipping costs shall be borne [Party responsible for shipping costs].4. Quality AssuranceThe Seller warrants that the vaccines are of good quality, meet all relevant standards and regulations, and are free from any defects or contaminants.5. Payment TermsThe Buyer shall make payment to the Seller within [number of days] days after the receipt of the vaccines. The payment shall be made in the following manner: [Payment Method]6. Inspection and AcceptanceThe Buyer has the right to inspect the vaccines upon delivery. If any non-conformity or defect is found, the Buyer shall notify the Seller within [number of days] days.7. Warranty and LiabilityThe Seller shall be liable for any damages or losses caused the quality or defect of the vaccines within the warranty period.8. Intellectual PropertyThe Seller shall ensure that the sale and use of the vaccines do not infringe any intellectual property rights.9. ConfidentialityBoth parties agree to keep the terms and conditions of this contract confidential.10. Force MajeureNeither party shall be liable for any flure or delay in performance due to force majeure events.11. Dispute ResolutionAny disputes arising from this contract shall be resolved through friendly negotiation. If negotiation fls, the dispute shall be submitted to arbitration or litigation in accordance with the applicable laws.12. Governing LawThis contract shall be governed the laws of [jurisdiction].13. Entire AgreementThis contract constitutes the entire agreement between the parties and supersedes all prior negotiations and understandings.IN WITNESS WHEREOF, the parties have executed this contract as of the date first above written.Buyer: [Buyer's Signature]Seller: [Seller's Signature]Date: [Date]。